Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in Ann Hematol

Retrieve available abstracts of 521 articles:
HTML format



Single Articles


    February 2025
  1. IBERTI M, Loschi M, Keslair F, Deckert M, et al
    Novel ETV6::RAPGEF6 fusion gene in chronic eosinophilic leukemia: compiling evidence on the role of IL3 overexpression in tumorigenesis.
    Ann Hematol. 2025 Feb 9. doi: 10.1007/s00277-025-06217.
    PubMed     Abstract available


  2. IYAMA S, Chi S, Idogawa M, Ikezoe T, et al
    Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study.
    Ann Hematol. 2025 Feb 8. doi: 10.1007/s00277-025-06227.
    PubMed     Abstract available


  3. SHUMILOV E, Mazzeo P, Trautmann M, Levien L, et al
    Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia.
    Ann Hematol. 2025 Feb 6. doi: 10.1007/s00277-025-06230.
    PubMed     Abstract available


  4. SHAFIEIZADEGAN S, Aberuyi N, Rahgozar S
    The molecular impact of miR-326 in acute lymphoblastic leukemia and its cross talk with P53.
    Ann Hematol. 2025 Feb 5. doi: 10.1007/s00277-024-06181.
    PubMed     Abstract available


    January 2025
  5. YIGIT KAYA S, Vatani M, Akil R, Cakir T, et al
    A complete response with daratumumab, venetoclax, azacitidine and dexamethasone in a heavily pre-treated, chemo-refractory early T-precursor acute lymphoblastic leukemia/lymphoma patient.
    Ann Hematol. 2025 Jan 23. doi: 10.1007/s00277-024-06118.
    PubMed     Abstract available


  6. ZHENG J, Zhou Y, Zhao Y, Luo Y, et al
    Adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation and tyrosine kinase inhibitors: development and validation of a clinical prediction model based on cytogene
    Ann Hematol. 2025 Jan 23. doi: 10.1007/s00277-025-06202.
    PubMed     Abstract available


  7. HIDALGO-GOMEZ G, Tazon-Vega B, Palacio C, Saumell S, et al
    How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jan 23. doi: 10.1007/s00277-024-06151.
    PubMed     Abstract available


  8. MASUDA Y, Sadato D, Toya T, Hirama C, et al
    Telomere shortening in donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation: a case report.
    Ann Hematol. 2025 Jan 22. doi: 10.1007/s00277-025-06222.
    PubMed     Abstract available


  9. YE Y, Zhao Z, Mo W, Liu W, et al
    Zebrafish modeling of atypical PML-RARA isoform from acute promyelocytic leukemia patient and its implications for clinical treatment.
    Ann Hematol. 2025 Jan 21. doi: 10.1007/s00277-024-06169.
    PubMed     Abstract available


  10. SOSSA-MELO C, Abello-Polo V, Salazar LA, Pena AM, et al
    Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 years or older in Colombia: a RENEHOC-PETHEMA study.
    Ann Hematol. 2025 Jan 16. doi: 10.1007/s00277-024-06120.
    PubMed     Abstract available


  11. KONG J, Zheng FM, Yan CH, Wang JZ, et al
    Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jan 16. doi: 10.1007/s00277-025-06198.
    PubMed     Abstract available


  12. SCHULZ F, Roggenbuck C, Kundgen A, Kasprzak A, et al
    Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.
    Ann Hematol. 2025 Jan 11. doi: 10.1007/s00277-025-06196.
    PubMed     Abstract available


  13. SHAKEEL L, Khaliq N, Shaukat A, Khan A, et al
    The efficacy and safety of nelarabine in relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-024-06121.
    PubMed     Abstract available


  14. YOUSEFI A, Levin MD, Cornelissen JJ, Westerweel PE, et al
    Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases.
    Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-024-06170.
    PubMed     Abstract available


  15. JIMBO K, Ishigaki T, Sakashita M, Andoh S, et al
    Prognosis of aggressive adult T-cell leukemia/lymphoma with central nervous system infiltration and utility of CD7 versus CADM1 flowcytometric plots of cerebrospinal fluid.
    Ann Hematol. 2025 Jan 10. doi: 10.1007/s00277-025-06186.
    PubMed     Abstract available


  16. JIN S, Chang M, Feng L, Hao Y, et al
    PEG-rhG-CSF versus rhG-CSF in supporting neutrophil recovery after induction chemotherapy for patients with newly diagnosed acute lymphoblastic leukemia.
    Ann Hematol. 2025 Jan 8. doi: 10.1007/s00277-025-06183.
    PubMed     Abstract available


  17. BUZZATTI E, Botti C, Presicci R, Mauro C, et al
    A fatal case of peritonitis due to colonic localization of acute myeloid leukemia.
    Ann Hematol. 2025 Jan 7. doi: 10.1007/s00277-024-06172.
    PubMed     Abstract available


  18. OH YE, Min GJ, Jeon YW, Kim TY, et al
    Long-term clinical outcome of a weekly 2-chlorodeoxyadenosine regimen in treatment-naive patients with hairy cell leukemia.
    Ann Hematol. 2025 Jan 4. doi: 10.1007/s00277-024-06173.
    PubMed     Abstract available


    December 2024
  19. LIU Q, Zhao J, Li Y, Jia Y, et al
    Comparative safety of different first-line treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic review and network meta-analysis.
    Ann Hematol. 2024 Dec 28. doi: 10.1007/s00277-024-06136.
    PubMed     Abstract available


  20. ZHAO Y, Yu X, Yan L, Shi D, et al
    Study on clinical features of early death in older patients with acute promyelocytic leukemia.
    Ann Hematol. 2024 Dec 27. doi: 10.1007/s00277-024-06165.
    PubMed     Abstract available


  21. SUGIHARA A, Kubota Y, Nagaie T, Fujita M, et al
    Epstein-Barr virus-associated lymphoproliferative disease during remission after induction therapy with dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report.
    Ann Hematol. 2024 Dec 21. doi: 10.1007/s00277-024-06153.
    PubMed     Abstract available


  22. MA JF, Yan CL, Jia X, Zhu HJ, et al
    Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma.
    Ann Hematol. 2024 Dec 18. doi: 10.1007/s00277-024-06132.
    PubMed     Abstract available


  23. TANG X, Liu S, Hu Y, Chen F, et al
    Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry.
    Ann Hematol. 2024 Dec 13. doi: 10.1007/s00277-024-06126.
    PubMed     Abstract available


  24. LI W, Ma R, Fan X, Xiao Z, et al
    M1 macrophage-derived exosomes alleviate leukemia by causing mitochondrial dysfunction.
    Ann Hematol. 2024 Dec 12. doi: 10.1007/s00277-024-06138.
    PubMed     Abstract available


  25. SANCHEZ-MENDOZA SE, de Deus-Wagatsuma VM, do Nascimento MC, Lima K, et al
    All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations.
    Ann Hematol. 2024 Dec 11. doi: 10.1007/s00277-024-06089.
    PubMed     Abstract available


  26. CHANSWANGPHUWANA C, Sukswai N, Tangnuntachai N, Rojnuckarin P, et al
    Survival impact of hypoxia-inducible factor-1 alpha (HIF-1alpha) in Nucleophosmin1 mutated acute myeloid leukemia.
    Ann Hematol. 2024 Dec 4. doi: 10.1007/s00277-024-06124.
    PubMed     Abstract available


  27. MATSUKAWA T, Onozawa M, Kondo T, Kanaya M, et al
    FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML.
    Ann Hematol. 2024;103:5333-5340.
    PubMed     Abstract available


  28. TAUVERON-JALENQUES U, Sarr K, Guieze R, Giordano C, et al
    Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia.
    Ann Hematol. 2024;103:5985-5988.
    PubMed     Abstract available


  29. BIN T, Tang J, Lu B, Xu XJ, et al
    Construction of AML prognostic model with CYP2E1 and GALNT12 biomarkers based on golgi- associated genes.
    Ann Hematol. 2024;103:5297-5314.
    PubMed     Abstract available


  30. KOUIDRI K, Acker F, Toenges R, Pfaff S, et al
    Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.
    Ann Hematol. 2024;103:5387-5393.
    PubMed     Abstract available


  31. CUI K, Zhang S, Wang Q, Wei Y, et al
    Prognostic significance of early nk cell recovery in pediatric t-cell replete allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:5769-5780.
    PubMed     Abstract available


  32. PUZO CJ, Hager KM, Rinder HM, Weinberg OK, et al
    Overall survival in TP53-mutated AML and MDS.
    Ann Hematol. 2024;103:5359-5369.
    PubMed     Abstract available


  33. LEE BJ, Griffin SP, Doh J, Ciurea SO, et al
    Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience.
    Ann Hematol. 2024;103:5395-5403.
    PubMed     Abstract available


  34. SUN Y, Wang Q, Zhang Z, Wang Q, et al
    Distinct clinical profiles and patient outcomes in aCML and CNL.
    Ann Hematol. 2024;103:5325-5332.
    PubMed     Abstract available


  35. HAN X, Liu W, Kang Z, Li D, et al
    Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis.
    Ann Hematol. 2024;103:4943-4952.
    PubMed     Abstract available


  36. JAFARI PA, Bagheri R, Lavasani S, Goudarzi S, et al
    DNMT3A-R882: a mutation with many paradoxes.
    Ann Hematol. 2024;103:4981-4988.
    PubMed     Abstract available


    November 2024
  37. BERNARDI S, Cavalleri A, Mutti S, Garuffo L, et al
    Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study.
    Ann Hematol. 2024 Nov 29. doi: 10.1007/s00277-024-06100.
    PubMed     Abstract available


  38. LI J, Chen J, Wang Q, Ou J, et al
    Clonal evolution defines risk stratification for central nervous system leukemia in adult acute lymphoblastic leukemia.
    Ann Hematol. 2024 Nov 29. doi: 10.1007/s00277-024-06116.
    PubMed     Abstract available


  39. ZHA C, Yang X, Yang J, Zhang Y, et al
    Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies.
    Ann Hematol. 2024 Nov 28. doi: 10.1007/s00277-024-06117.
    PubMed     Abstract available


  40. LI Y, Zhang Q, Shao H
    Recurrent PAX5::ZCCHC7 rearrangement in B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2024 Nov 27. doi: 10.1007/s00277-024-06114.
    PubMed     Abstract available


  41. ABDELFATTAH NE, Elsayed GM, Soliman AH, Ebeid EN, et al
    Copy number alterations in pediatric B-cell precursor acute lymphoblastic leukemia patients and their association with patients' outcome.
    Ann Hematol. 2024 Nov 26. doi: 10.1007/s00277-024-06102.
    PubMed     Abstract available


  42. MA H, Du Y, Li J, Rao J, et al
    Venetoclax plus D-CAG (decitabine, cytarabine, aclarubicin, G-CSF) for elderly or unfit patients with newly diagnosed acute myeloid leukemia: a multicenter, prospective study.
    Ann Hematol. 2024 Nov 26. doi: 10.1007/s00277-024-06097.
    PubMed     Abstract available


  43. HE Y, Ding J, Liu L, Chen J, et al
    Investigation of TSRP reverses imatinib resistance through the PI3K / Akt pathway in chronic myeloid leukemia.
    Ann Hematol. 2024 Nov 25. doi: 10.1007/s00277-024-06099.
    PubMed     Abstract available


  44. CHEN X, Ma X, Yuan L, Wang F, et al
    The second adult case of NUTM1 fusion-positive B-cell lymphoblastic leukemia: A recurring pattern of poor prognosis.
    Ann Hematol. 2024 Nov 25. doi: 10.1007/s00277-024-06115.
    PubMed     Abstract available


  45. FLEISCHMANN M, Jentzsch M, Brioli A, Eisele F, et al
    Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
    Ann Hematol. 2024 Nov 20. doi: 10.1007/s00277-024-06095.
    PubMed    


  46. BLANKSTEIN AR, Choi N, Mozessohn L, Sanford D, et al
    Supportive care strategies in myelodysplastic syndromes and acute myeloid leukemia in older adults: a national survey of Canadian hematologists.
    Ann Hematol. 2024 Nov 20. doi: 10.1007/s00277-024-06085.
    PubMed     Abstract available


  47. MIZUNO S, Hosoi H, Takami A, Kawata T, et al
    Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2024 Nov 19. doi: 10.1007/s00277-024-06094.
    PubMed     Abstract available


  48. AU WY, Chow C, To KF, Ma ESK, et al
    Mixed-phenotype leukemia with TCF3::ZNF384 fusion presenting as an isolated mediastinal mass.
    Ann Hematol. 2024 Nov 12. doi: 10.1007/s00277-024-06042.
    PubMed     Abstract available


  49. TOLOZA MJ, Lincango M, Camacho MF, Ledesma MM, et al
    Immune checkpoints PD1/PDL1, TIM3/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia.
    Ann Hematol. 2024 Nov 7. doi: 10.1007/s00277-024-06074.
    PubMed     Abstract available


  50. MONSEREENUSORN C, Techavichit P, Sathitsamitphong L, Lertvivatpong N, et al
    Enhancing outcomes of childhood acute lymphoblastic leukemia in workplace diversity in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
    Ann Hematol. 2024 Nov 5. doi: 10.1007/s00277-024-06068.
    PubMed     Abstract available


  51. HUANG N, Chang C, Wu L, He Q, et al
    Distinct mutation features and its clinical significance in myelodysplastic syndromes with normal karyotype.
    Ann Hematol. 2024;103:4485-4495.
    PubMed     Abstract available


  52. SPATH C, Neumann T, Kruger WH
    Antileukaemic rescue by dose-dense donor-lymphocyte infusions in T-PLL after allogeneic stem cell transplantation - a case report.
    Ann Hematol. 2024;103:4777-4778.
    PubMed     Abstract available


    October 2024
  53. ZHENG S, Tong Y, Yang L, Chen J, et al
    The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment.
    Ann Hematol. 2024 Oct 29. doi: 10.1007/s00277-024-06050.
    PubMed     Abstract available


  54. FORGHIERI F, Bettelli F, Sgromo S, Nadali G, et al
    Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group.
    Ann Hematol. 2024 Oct 28. doi: 10.1007/s00277-024-06047.
    PubMed    


  55. MCCLELLAN K, Messina J, Saullo J, Huggins J, et al
    Incidence of infection in patients with acute myeloid leukemia receiving high-dose cytarabine consolidation.
    Ann Hematol. 2024 Oct 27. doi: 10.1007/s00277-024-06069.
    PubMed     Abstract available


  56. FLEISCHMANN M, Jentzsch M, Brioli A, Eisele F, et al
    Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
    Ann Hematol. 2024 Oct 25. doi: 10.1007/s00277-024-06048.
    PubMed     Abstract available


  57. EFFICACE F, Sparano F, Breccia M, Greco C, et al
    Health-related quality of life benefits of arsenic trioxide in patients with non-high-risk acute promyelocytic leukemia are sustained over time: long-term results of the GIMEMA APL0406 trial.
    Ann Hematol. 2024 Oct 23. doi: 10.1007/s00277-024-06038.
    PubMed     Abstract available


  58. LI S, Gao R, Han X, Wang K, et al
    MALAT1/miR-582-5p/GALNT1/MUC1 axis modulates progression of AML leukemia stem cells by regulating JAK2/STAT3 pathway.
    Ann Hematol. 2024 Oct 21. doi: 10.1007/s00277-024-06043.
    PubMed     Abstract available


  59. TRIPATHI S, K V VB, Nayak AR, Chauhan R, et al
    Ischemic stroke as a presenting feature of promyelocytic blast phase in chronic myeloid leukemia - an uncommon presentation: a case report and literature review in the post imatinib era.
    Ann Hematol. 2024 Oct 16. doi: 10.1007/s00277-024-06044.
    PubMed     Abstract available


  60. SCALZULLI E, Costa A, Carmosino I, Musiu P, et al
    Different prognosis according to treatment in patients with acute promyelocytic leukemia: How the outcome changed over time.
    Ann Hematol. 2024 Oct 15. doi: 10.1007/s00277-024-06014.
    PubMed     Abstract available


  61. ZHU Y, Huang J, Wang Y, Han Y, et al
    Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2024 Oct 14. doi: 10.1007/s00277-024-06027.
    PubMed     Abstract available


  62. YANG L, Ma D, Liu S, Zou L, et al
    The DHODH inhibitor teriflunomide impedes cell proliferation and enhances chemosensitivity to daunorubicin (DNR) in T-cell acute lymphoblastic leukemia.
    Ann Hematol. 2024 Oct 8. doi: 10.1007/s00277-024-05998.
    PubMed     Abstract available


  63. WERY AR, Salaroli A, Andreozzi F, Paesmans M, et al
    Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study.
    Ann Hematol. 2024 Oct 4. doi: 10.1007/s00277-024-06017.
    PubMed     Abstract available


  64. LI HD, Chen SS, Ding J, Zhang CL, et al
    Exploration of ETV6::ABL1-positive AML with concurrent NPM1 and FLT3-ITD mutations.
    Ann Hematol. 2024;103:4295-4304.
    PubMed     Abstract available


  65. CHEN CY
    Chromothripsis in myeloid malignancies.
    Ann Hematol. 2024;103:3955-3962.
    PubMed     Abstract available


  66. GAO Y, Xi Y, Chen W, Meng Y, et al
    Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide.
    Ann Hematol. 2024;103:3947-3954.
    PubMed     Abstract available


  67. GE S, Wang J, He Q, Zhu J, et al
    Auto-hematopoietic stem cell transplantation or chemotherapy? Meta-analysis of clinical choice for AML.
    Ann Hematol. 2024;103:3855-3866.
    PubMed     Abstract available


    September 2024
  68. PAN YS, Li H, Yang M, Zhang CL, et al
    A case of visual impairment due to HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation in childhood acute myeloid leukemia-M2 subtype.
    Ann Hematol. 2024 Sep 30. doi: 10.1007/s00277-024-06030.
    PubMed     Abstract available


  69. AHMAD F, Shah A, Angi M, Narmawala Q, et al
    Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report.
    Ann Hematol. 2024 Sep 27. doi: 10.1007/s00277-024-05966.
    PubMed     Abstract available


  70. HAGIHARA M, Yasu T, Gando Y, Sugi T, et al
    Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia.
    Ann Hematol. 2024 Sep 27. doi: 10.1007/s00277-024-05845.
    PubMed     Abstract available


  71. KRAMP LJ, Heydrich-Karsten C, Sembill S, Karow A, et al
    CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase.
    Ann Hematol. 2024 Sep 21. doi: 10.1007/s00277-024-06011.
    PubMed     Abstract available


  72. DUAN W, Jia J, Wang J, Liu X, et al
    Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival.
    Ann Hematol. 2024 Sep 17. doi: 10.1007/s00277-024-06001.
    PubMed     Abstract available


  73. ZHAO Z, Lan J
    Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia.
    Ann Hematol. 2024 Sep 16. doi: 10.1007/s00277-024-06008.
    PubMed     Abstract available


  74. YANG S, Huang H, Zhou K, Zhao X, et al
    Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial.
    Ann Hematol. 2024 Sep 14. doi: 10.1007/s00277-024-05978.
    PubMed     Abstract available


  75. PEREZ-LAMAS L, Diaz AS, Castera EM, Soto MH, et al
    Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.
    Ann Hematol. 2024 Sep 13. doi: 10.1007/s00277-024-05906.
    PubMed     Abstract available


  76. ATNAF A, Akelew Y, Abebaw D, Muche Y, et al
    The role of long noncoding RNAs in the diagnosis, prognosis and therapeutic biomarkers of acute myeloid leukemia.
    Ann Hematol. 2024 Sep 12. doi: 10.1007/s00277-024-05987.
    PubMed     Abstract available


  77. HAN P, Wei S, Wang H, Cai Y, et al
    Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade.
    Ann Hematol. 2024 Sep 12. doi: 10.1007/s00277-024-06003.
    PubMed     Abstract available


  78. SIFFEL C, Richter J, Anderson-Smits C, Kamieniak M, et al
    Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study.
    Ann Hematol. 2024 Sep 12. doi: 10.1007/s00277-024-05984.
    PubMed     Abstract available


  79. JAIN AG, Volpe VO, Wang C, Ball S, et al
    Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia.
    Ann Hematol. 2024 Sep 7. doi: 10.1007/s00277-024-05976.
    PubMed     Abstract available


  80. WEI Y, Qian K, Le N, Wang L, et al
    Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study.
    Ann Hematol. 2024 Sep 7. doi: 10.1007/s00277-024-05972.
    PubMed     Abstract available


  81. STEINER N, Baier K, Ritter D, Rudzki J, et al
    Early autologous and/or allogeneic stem cell transplantation for adult patients with advanced stage T- lymphoblastic leukemia/lymphoma or Burkitt lymphoma. A retrospective single-centre analysis.
    Ann Hematol. 2024 Sep 3. doi: 10.1007/s00277-024-05979.
    PubMed     Abstract available


  82. TALEBI E, Ghoraeian P, Shams Z, Rahimi H, et al
    Molecular insights into the hedgehog signaling pathway correlated non-coding RNAs in acute lymphoblastic leukemia, a bioinformatics study.
    Ann Hematol. 2024 Sep 3. doi: 10.1007/s00277-024-05763.
    PubMed     Abstract available


  83. SOBAS M, Ianotto JC, Kiladjian JJ, Harrison C, et al
    Myeloproliferative neoplasms: young patients, current data and future considerations.
    Ann Hematol. 2024;103:3287-3291.
    PubMed     Abstract available


  84. GUARNERA L, Tiravanti I, Guiducci A, Coppola L, et al
    Prophylaxis with Tixagevimab/Cilgavimab in chronic lymphocytic leukaemia, a case control study.
    Ann Hematol. 2024;103:3831-3833.
    PubMed    


  85. HUA W, Qi J, Zhou M, Han S, et al
    Overexpression of REC8 induces aberrant gamete meiotic division and contributes to AML pathogenesis - a multiplexed microarray analysis and mendelian randomization study.
    Ann Hematol. 2024;103:3563-3572.
    PubMed     Abstract available


  86. COX ER, Summers C, Milano F, Dahlberg A, et al
    Outcomes of patients undergoing third hematopoietic cell transplantation for hematologic malignancies.
    Ann Hematol. 2024;103:3737-3743.
    PubMed     Abstract available


  87. CHEN F
    ETV6::ABL1 positive myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK) with blast crisis treated with flumatinib mesylate.
    Ann Hematol. 2024;103:3801-3804.
    PubMed     Abstract available


  88. ROZENTAL A, Halperin E, Leibovitch C, Barzili M, et al
    CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study.
    Ann Hematol. 2024;103:3585-3594.
    PubMed     Abstract available


  89. HU L, Li Z, Yang S, Zhao T, et al
    Allogeneic stem cell transplantation is still a highly curative therapy in adults with philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Ann Hematol. 2024;103:3745-3754.
    PubMed     Abstract available


  90. YANG M, Tang Y, Zhu P, Lu H, et al
    The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic Leukaemia.
    Ann Hematol. 2024;103:3385-3398.
    PubMed     Abstract available


  91. WEI Z, Su L, Gao S
    The roles of ubiquitination in AML.
    Ann Hematol. 2024;103:3413-3428.
    PubMed     Abstract available


    August 2024
  92. XU Q, Li H, Huang P, Lin W, et al
    Investigation of infections status in pediatric patients with acute myeloid leukemia during the induction period-a retrospective study in two medical centers.
    Ann Hematol. 2024 Aug 31. doi: 10.1007/s00277-024-05939.
    PubMed     Abstract available


  93. JIMENEZ-VICENTE C, Guardia-Torrelles A, Perez-Valencia AI, Martinez-Roca A, et al
    Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study.
    Ann Hematol. 2024 Aug 29. doi: 10.1007/s00277-024-05923.
    PubMed     Abstract available


  94. KLOS C, Roynard P, Berthon C, Soenen V, et al
    Unravelling a KMT2A::ARHGEF12 fusion within chromoanagenesis in acute myeloid leukemia using Optical Genome Mapping.
    Ann Hematol. 2024 Aug 29. doi: 10.1007/s00277-024-05948.
    PubMed    


  95. PRAJAPATI SK, Kumari N, Bhowmik D, Gupta R, et al
    Recent advancements in biomarkers, therapeutics, and associated challenges in acute myeloid leukemia.
    Ann Hematol. 2024 Aug 29. doi: 10.1007/s00277-024-05963.
    PubMed     Abstract available


  96. SOLIS-ARMENTA R, Rodriguez-Rodriguez S, Hernandez-Perez AP, Paulina-Zapata N, et al
    Understanding factors limiting hematopoietic cell transplantation for acute myeloid leukemia patients in Mexico: a comprehensive analysis.
    Ann Hematol. 2024 Aug 23. doi: 10.1007/s00277-024-05956.
    PubMed     Abstract available


  97. BADER MS, Kubetzko S, Schafer BW, Arranto C, et al
    Minimal residual disease monitoring by Ig/TCR gene rearrangements predicts post-transplant relapse and survival in adult patients with acute lymphoblastic leukemia.
    Ann Hematol. 2024 Aug 21. doi: 10.1007/s00277-024-05943.
    PubMed    


  98. MENG Z, Zheng H, Liu Y, Guo X, et al
    Prognostic significance of CRLF2 in patients with acute lymphoblastic leukemia: a meta-analysis and systematic review.
    Ann Hematol. 2024 Aug 21. doi: 10.1007/s00277-024-05667.
    PubMed     Abstract available


  99. YANG Y, Wang L, Peng Y, Nie X, et al
    Analysis of the occurrence and liver function characteristics of arsenic-associated liver injury during the treatment of pediatric patients with acute promyelocytic leukemia.
    Ann Hematol. 2024 Aug 21. doi: 10.1007/s00277-024-05954.
    PubMed     Abstract available


  100. SUGITA J, Morita K, Konuma T, Yanada M, et al
    Allogeneic hematopoietic cell transplantation from alternative donors in acute myeloid leukemia.
    Ann Hematol. 2024 Aug 17. doi: 10.1007/s00277-024-05944.
    PubMed     Abstract available


  101. NUNES RAB, Avezum A, de Oliveira Marques M, Baiocchi OCCG, et al
    Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
    Ann Hematol. 2024 Aug 17. doi: 10.1007/s00277-024-05921.
    PubMed     Abstract available


  102. TARANTINI F, Cumbo C, Parciante E, Anelli L, et al
    IRF4 dysregulation in chronic myelomonocytic leukemia: another brick in the wall of myelodysplastic/myeloproliferative neoplasms.
    Ann Hematol. 2024 Aug 15. doi: 10.1007/s00277-024-05938.
    PubMed    


  103. YAO Y, Zhou J, Li Y, Shi S, et al
    CD19 CAR T-cell therapy in relapsed TCF3-HLF-positive B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2024 Aug 15. doi: 10.1007/s00277-024-05945.
    PubMed    


  104. SU Z, Cong B, Dong P
    A novel FNDC3B::MECOM fusion gene accompanied with Der(5; 17)(p10; q10) in acute myelocytic leukemia.
    Ann Hematol. 2024 Aug 14. doi: 10.1007/s00277-024-05930.
    PubMed    


  105. LAU C, van Kesteren C, Cao YX, Smeenk RM, et al
    Varying concentrations of tyrosine kinase inhibitors in chronic myeloid leukemia patients following bariatric surgery: a case series.
    Ann Hematol. 2024 Aug 12. doi: 10.1007/s00277-024-05924.
    PubMed     Abstract available


  106. FORGHIERI F, Cordella S, Marchesi F, Itri F, et al
    Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemi
    Ann Hematol. 2024 Aug 8. doi: 10.1007/s00277-024-05927.
    PubMed    


  107. WANG SX, Wang F, Tu YC, Zhou YL, et al
    Rare case of simultaneous occurrence of chronic neutrophil leukemia and T lymphoblastic lymphoma: case report and literature review.
    Ann Hematol. 2024 Aug 6. doi: 10.1007/s00277-024-05759.
    PubMed     Abstract available


  108. TAMELLINI E, Simio C, Bernardelli A, Ferrarini I, et al
    Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report.
    Ann Hematol. 2024 Aug 3. doi: 10.1007/s00277-024-05922.
    PubMed     Abstract available


  109. GUO W, Zhang H, Wang M, Zheng Y, et al
    WT1 gene mutations impact post-transplant relapse in myelodysplastic syndrome with excess blasts 2 patients.
    Ann Hematol. 2024;103:2827-2836.
    PubMed     Abstract available


  110. CHOQUET S, Marchal C, Deygas F, Deslandes M, et al
    A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS).
    Ann Hematol. 2024;103:2969-2981.
    PubMed     Abstract available


  111. GUO W, Zhang H, Zheng Y, Gao H, et al
    Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT.
    Ann Hematol. 2024;103:3155-3163.
    PubMed     Abstract available


  112. SUAREZ EU, Boluda B, Lavilla E, Tormo M, et al
    Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
    Ann Hematol. 2024;103:2845-2851.
    PubMed     Abstract available


  113. SHI H, Yang F, Cao M, Xu T, et al
    Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.
    Ann Hematol. 2024;103:2993-3004.
    PubMed     Abstract available


  114. KT MF, Semwal M, Yoosuf BT, Lad D, et al
    Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS.
    Ann Hematol. 2024;103:3179-3191.
    PubMed     Abstract available


  115. HU R, Liao P, Xu B, Qiu Y, et al
    N6-methyladenosine RNA modifications: a potential therapeutic target for AML.
    Ann Hematol. 2024;103:2601-2612.
    PubMed     Abstract available


    July 2024
  116. DENG J, Qin X, Ma G, Shen X, et al
    Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.
    Ann Hematol. 2024 Jul 29. doi: 10.1007/s00277-024-05862.
    PubMed     Abstract available


  117. FAN BE, Chow M
    Artificial intelligence assisted diagnosis of chronic lymphocytic leukemia in a historic pediatric case using large language models.
    Ann Hematol. 2024 Jul 29. doi: 10.1007/s00277-024-05916.
    PubMed    


  118. ROBAK T, Pula A, Braun M, Robak E, et al
    Extramedullary and extranodal manifestations in chronic lymphocytic leukemia - an update.
    Ann Hematol. 2024 Jul 25. doi: 10.1007/s00277-024-05854.
    PubMed     Abstract available


  119. DAI Y, Luo L, Wei Z, Cheng P, et al
    The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience.
    Ann Hematol. 2024 Jul 24. doi: 10.1007/s00277-024-05892.
    PubMed     Abstract available


  120. LIPTON JH, Brummendorf TH, Sweet K, Apperley JF, et al
    Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia.
    Ann Hematol. 2024 Jul 18. doi: 10.1007/s00277-024-05851.
    PubMed     Abstract available


  121. ZHAO Y, Huang Y, Jiang L, Zhang Y, et al
    Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.
    Ann Hematol. 2024 Jul 18. doi: 10.1007/s00277-024-05884.
    PubMed     Abstract available


  122. KONTANDREOPOULOU CN, Solomou EE, Kolorizos E, Diamantopoulos PT, et al
    Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.
    Ann Hematol. 2024 Jul 15. doi: 10.1007/s00277-024-05869.
    PubMed     Abstract available


  123. CAO HY, Li HY, Cai WZ, Huang YH, et al
    Genetic and clinical characteristics of acute B-cell lymphoblastic leukemia with MEF2D fusions and report of two novel MEF2D rearrangements.
    Ann Hematol. 2024 Jul 11. doi: 10.1007/s00277-024-05868.
    PubMed     Abstract available


  124. BUDAK B, Tukel EY, Turanli B, Kiraz Y, et al
    Correction to: Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities.
    Ann Hematol. 2024 Jul 11. doi: 10.1007/s00277-024-05881.
    PubMed    


  125. LAIMON DN, Sakr DH, Atef B, Shaaban Y, et al
    Highlights of ophthalmological manifestations in newly diagnosed acute leukemia: a correlation with hematological parameters.
    Ann Hematol. 2024 Jul 10. doi: 10.1007/s00277-024-05861.
    PubMed     Abstract available


  126. SINGH S, Lionel S, Jain H, Rajendra A, et al
    Treatment challenges and outcomes of older patients with acute myeloid leukemia from India.
    Ann Hematol. 2024 Jul 8. doi: 10.1007/s00277-024-05873.
    PubMed     Abstract available


  127. ZHENG J, Zhao Y, Luo Y, Yu J, et al
    Impact of additional cytogenetic aberrations at diagnosis on prognosis of adults patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: a retrospective analysis.
    Ann Hematol. 2024 Jul 4. doi: 10.1007/s00277-024-05871.
    PubMed     Abstract available


  128. WANG J, Mu M, Zhu J, Yang J, et al
    Adult acute leukemia patients with gram-negative bacteria bloodstream infection: Risk factors and outcomes of antibiotic-resistant bacteria.
    Ann Hematol. 2024 Jul 3. doi: 10.1007/s00277-024-05866.
    PubMed     Abstract available


  129. CHEN R, Tao Q, Wu F, Zhai Z, et al
    DNT cells mediate resistance to CAR-T cells therapy in a pediatric patient with relapsed and refractory B-ALL.
    Ann Hematol. 2024;103:2551-2556.
    PubMed     Abstract available


  130. PANDA D, Tejwani N, Pandey P, Mehta A, et al
    Myeloid sarcoma with RAM phenotype in an adult male presenting with CNS relapse; no longer a pediatric disease.
    Ann Hematol. 2024;103:2561-2563.
    PubMed    


  131. CHEN Y, Chen Y, Wu Z, Li J, et al
    Nomogram predictive models for adult patients with acute lymphoblastic leukaemia based on real-world treatment outcomes.
    Ann Hematol. 2024;103:2393-2404.
    PubMed     Abstract available


    June 2024
  132. GONG Y, Li Y, Chen X, Yang H, et al
    Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib.
    Ann Hematol. 2024 Jun 27. doi: 10.1007/s00277-024-05856.
    PubMed     Abstract available


  133. SHI Y, Chen X, Jin H, Zhu L, et al
    Correction to: Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.
    Ann Hematol. 2024 Jun 24. doi: 10.1007/s00277-024-05812.
    PubMed    


  134. CAO X, Li Z, Zhang Y, Cui Q, et al
    Chidamide combined with a modified Bu-Cy conditioning regimen improves survival in patients with T-cell acute lymphoblastic leukemia/lymphoma undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024 Jun 20. doi: 10.1007/s00277-024-05849.
    PubMed     Abstract available


  135. ZHOU K, Wang T, Pan L, Xu W, et al
    Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE.
    Ann Hematol. 2024 Jun 18. doi: 10.1007/s00277-024-05823.
    PubMed     Abstract available


  136. WANG XZ, Gao XM, Wang JM, Cai H, et al
    Co-occurrence of Erdheim-Chester disease and clonally evolving acute myeloid leukemia with FLT3-ITD and PTPN11 mutations.
    Ann Hematol. 2024 Jun 15. doi: 10.1007/s00277-024-05842.
    PubMed     Abstract available


  137. ABULIMITI M, Jia ZY, Wu Y, Yu J, et al
    Exploring and clinical validation of prognostic significance and therapeutic implications of copper homeostasis-related gene dysregulation in acute myeloid leukemia.
    Ann Hematol. 2024 Jun 15. doi: 10.1007/s00277-024-05841.
    PubMed     Abstract available


  138. LI T, Wu P, Wang A, Chen M, et al
    A HNRNPC::RARB variant of acute promyelocytic leukemia with concurrent myeloid sarcoma of the spine.
    Ann Hematol. 2024 Jun 12. doi: 10.1007/s00277-024-05833.
    PubMed    


  139. ZHANG Z, Fu C, Sun Y, Liu Y, et al
    High hyperdiploid karyotype with >/= 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China.
    Ann Hematol. 2024 Jun 8. doi: 10.1007/s00277-024-05834.
    PubMed     Abstract available


  140. WEI D, Liang X, Huang M, Wang C, et al
    Targeting histone deacetylase 1 (HDAC1) in the bone marrow stromal cells revers imatinib resistance by modulating IL-6 in Ph + acute lymphoblastic leukemia.
    Ann Hematol. 2024 Jun 7. doi: 10.1007/s00277-024-05830.
    PubMed     Abstract available


  141. BOUCHLA A, Sotiropoulou CD, Esteb C, Loupis T, et al
    Silencing of the DNA damage repair regulator PPP1R15A sensitizes acute myeloid leukemia cells to chemotherapy.
    Ann Hematol. 2024 Jun 6. doi: 10.1007/s00277-024-05785.
    PubMed     Abstract available


  142. BUDAK B, Tukel EY, Turanli B, Kiraz Y, et al
    Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities.
    Ann Hematol. 2024 Jun 5. doi: 10.1007/s00277-024-05821.
    PubMed     Abstract available


  143. ZHENG B, Geng Y, Li Y, Huang H, et al
    Specificity protein 1/3 regulate T-cell acute lymphoblastic leukemia cell proliferation and apoptosis through beta-catenin by acting as targets of miR-495-3p.
    Ann Hematol. 2024 Jun 3. doi: 10.1007/s00277-024-05764.
    PubMed     Abstract available


  144. JAIN AG, Gesiotto Q, Ball S, Nodzon L, et al
    Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
    Ann Hematol. 2024;103:1941-1945.
    PubMed     Abstract available


    May 2024
  145. LI Y, Zhang Q, Shao H
    Chemotherapy vs. "TKI + immunotherapy" in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene.
    Ann Hematol. 2024 May 29. doi: 10.1007/s00277-024-05816.
    PubMed    


  146. WANG Q, Hu Y, Gao L, Zhang S, et al
    Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.
    Ann Hematol. 2024 May 28. doi: 10.1007/s00277-024-05810.
    PubMed     Abstract available


  147. BRAUN A, Otoukesh S, Tinajero J, Marcucci G, et al
    Blinatumomab-induced macrophage activating syndrome (MAS) in adult with B-cell acute lymphoblastic leukemia (B-ALL).
    Ann Hematol. 2024 May 24. doi: 10.1007/s00277-024-05795.
    PubMed     Abstract available


  148. IOVENE FR, Santinelli E, Armiento D, Sarlo C, et al
    Acute myeloid leukemia with paraneoplastic pemphigus successfully treated with a personalized antileukemic and immunosuppressive strategy.
    Ann Hematol. 2024 May 23. doi: 10.1007/s00277-024-05804.
    PubMed     Abstract available


  149. CUI T, Li H, Zhou S, Li J, et al
    Impact of cladribine, cytarabine, and G-CSF (CLAG) as a bridging therapy prior to allogeneic hematopoietic stem cell transplantation in relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2024 May 17. doi: 10.1007/s00277-024-05791.
    PubMed     Abstract available


  150. FONTECHA MB, Anadon MDR, Mercado Guzman V, Stanganelli C, et al
    Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants.
    Ann Hematol. 2024 May 14. doi: 10.1007/s00277-024-05794.
    PubMed     Abstract available


  151. TOLLE M, Gokbuget N, Habringer S, Keller U, et al
    Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia.
    Ann Hematol. 2024 May 11. doi: 10.1007/s00277-024-05789.
    PubMed    


  152. SHI Y, Chen X, Jin H, Zhu L, et al
    Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients.
    Ann Hematol. 2024 May 9. doi: 10.1007/s00277-024-05786.
    PubMed     Abstract available


  153. MITROVIC-AJTIC O, Zivkovic E, Suboticki T, Diklic M, et al
    Inflammation mediated angiogenesis in chronic lymphocytic leukemia.
    Ann Hematol. 2024 May 7. doi: 10.1007/s00277-024-05781.
    PubMed     Abstract available


  154. MENSHAWY NE, El-Ghonemy MS, Ebrahim MA, Fahmi MW, et al
    Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements.
    Ann Hematol. 2024 May 7. doi: 10.1007/s00277-024-05779.
    PubMed     Abstract available


  155. FRANKE GN, Loewe G, Reiser M, Linde H, et al
    Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices.
    Ann Hematol. 2024;103:1569-1575.
    PubMed     Abstract available


  156. NISCOLA P, Gianfelici V, Giovannini M, Piccioni D, et al
    Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
    Ann Hematol. 2024;103:1787-1788.
    PubMed    


  157. SHUMILOV E, Mazzeo P, Ghandili S, Kunstner A, et al
    Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations.
    Ann Hematol. 2024;103:1587-1599.
    PubMed     Abstract available


    April 2024
  158. LIU Y, Liu Y, Chen P, Chen G, et al
    GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy.
    Ann Hematol. 2024 Apr 27. doi: 10.1007/s00277-024-05777.
    PubMed     Abstract available


  159. TAZOE K, Harada N, Makuuchi Y, Kuno M, et al
    Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    Ann Hematol. 2024 Apr 25. doi: 10.1007/s00277-024-05772.
    PubMed     Abstract available


  160. BENCHIKH S, Charlene SSG, Bousfiha A, Razoki L, et al
    Cytogenetic and epidemiological profile of chronic myeloid leukemia in Morocco.
    Ann Hematol. 2024 Apr 24. doi: 10.1007/s00277-024-05747.
    PubMed     Abstract available


  161. THAU S, Poulsen CB, Brieghel C, Larsen MK, et al
    COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study.
    Ann Hematol. 2024 Apr 18. doi: 10.1007/s00277-024-05738.
    PubMed     Abstract available


  162. JEBANESAN DZP, Illangeswaran RSS, Rajamani BM, Vidhyadharan RT, et al
    Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.
    Ann Hematol. 2024 Apr 17. doi: 10.1007/s00277-024-05742.
    PubMed     Abstract available


  163. LEOTTA S, Markovic U, Duminuco A, Mule A, et al
    Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
    Ann Hematol. 2024 Apr 13. doi: 10.1007/s00277-024-05725.
    PubMed     Abstract available


  164. GU Z, Li F, Li M, Wang L, et al
    Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia/lymphoma in first complete remission: a single-center study.
    Ann Hematol. 2024 Apr 12. doi: 10.1007/s00277-024-05716.
    PubMed     Abstract available


  165. LUO L, Jiao Y, Li Y, Yang P, et al
    Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China.
    Ann Hematol. 2024 Apr 6. doi: 10.1007/s00277-024-05719.
    PubMed     Abstract available


  166. PEREZ-LAMAS L, de Paz Arias R, Diaz RMA, Montero LFC, et al
    Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.
    Ann Hematol. 2024 Apr 3. doi: 10.1007/s00277-024-05662.
    PubMed     Abstract available


  167. LIU S, Cui Q, Li M, Li Z, et al
    Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.
    Ann Hematol. 2024;103:1397-1402.
    PubMed     Abstract available


  168. REN Y, Liu F, Chen X, Zhang X, et al
    Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:1345-1351.
    PubMed     Abstract available


  169. LUCERO J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, et al
    Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:1187-1196.
    PubMed     Abstract available


  170. WANG J, Zhu H, Miao K
    Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report.
    Ann Hematol. 2024 Apr 1. doi: 10.1007/s00277-024-05714.
    PubMed     Abstract available


    March 2024
  171. CHEN Y, Pan M, Chen L, Peng M, et al
    Correction to: Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
    Ann Hematol. 2024 Mar 27. doi: 10.1007/s00277-024-05675.
    PubMed    


  172. WU CY, Yeh CM, Tsai CK, Liu CJ, et al
    The influence of hospital volume and physician volume on early mortality in acute promyelocytic leukemia patients.
    Ann Hematol. 2024 Mar 26. doi: 10.1007/s00277-024-05616.
    PubMed     Abstract available


  173. CAI X, Liu Y, Li H, Que Y, et al
    XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
    Ann Hematol. 2024 Mar 23. doi: 10.1007/s00277-024-05706.
    PubMed     Abstract available


  174. KUROSAWA S, Yokota T, Takada Y, Okubo S, et al
    Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report.
    Ann Hematol. 2024 Mar 21. doi: 10.1007/s00277-024-05721.
    PubMed    


  175. HUANG XT, Wang CJ, Gao C, Xue TL, et al
    Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.
    Ann Hematol. 2024 Mar 18. doi: 10.1007/s00277-024-05687.
    PubMed     Abstract available


  176. OU J, Deng S, Ding C, Cai Z, et al
    Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia.
    Ann Hematol. 2024 Mar 7. doi: 10.1007/s00277-024-05681.
    PubMed     Abstract available


  177. RORVIK SD, Torkildsen S, Bruserud O, Tvedt THA, et al
    Acute myeloid leukemia with rare recurring translocations-an overview of the entities included in the international consensus classification.
    Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05680.
    PubMed     Abstract available


  178. DARTIGEAS C, Quinquenel A, Ysebaert L, Dilhuydy MS, et al
    Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
    Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05666.
    PubMed     Abstract available


  179. WU X, Ma X, Song T, Liu J, et al
    The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping.
    Ann Hematol. 2024;103:917-933.
    PubMed     Abstract available


  180. KENNEDY A, Patel S, Ramanathan M, Gerber J, et al
    Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center.
    Ann Hematol. 2024;103:1031-1033.
    PubMed    


  181. KRECAK I, Cubric E, Smolic J, Vrbicic B, et al
    Small lymphocytic lymphoma infiltrating gastrointestinal tract and mimicking inflammatory bowel disease, successfully treated with acalabrutinib.
    Ann Hematol. 2024;103:1021-1023.
    PubMed    


  182. PALANI HK, Ganesan S, Balasundaram N, Venkatraman A, et al
    Cystatin F a potential diagnostic biomarker in acute promyelocytic leukemia.
    Ann Hematol. 2024 Mar 1. doi: 10.1007/s00277-024-05673.
    PubMed    


    February 2024
  183. SCHWANER I, Kuhn T, Losem C, Wolff T, et al
    Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
    Ann Hematol. 2024 Feb 29. doi: 10.1007/s00277-024-05638.
    PubMed     Abstract available


  184. CHEN Y, Zheng J, Weng Y, Wu Z, et al
    Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.
    Ann Hematol. 2024 Feb 27. doi: 10.1007/s00277-024-05679.
    PubMed     Abstract available


  185. TERAMOTO M, Tamaki H, Kaida K, Samori M, et al
    Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis.
    Ann Hematol. 2024 Feb 23. doi: 10.1007/s00277-024-05654.
    PubMed     Abstract available


  186. WANG X, Zhang Y, Xue S
    Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
    Ann Hematol. 2024 Feb 21. doi: 10.1007/s00277-023-05601.
    PubMed     Abstract available


  187. GOTO T, Nakamura N, Suzaki T, Shimazu R, et al
    A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration.
    Ann Hematol. 2024 Feb 20. doi: 10.1007/s00277-024-05660.
    PubMed    


  188. LI X, Zhou J, Li J, Zhu X, et al
    Effectiveness and safety of blinatumomab for pediatric B cell acute lymphoblastic leukemia with Loeffler's endocarditis.
    Ann Hematol. 2024 Feb 17. doi: 10.1007/s00277-024-05656.
    PubMed    


  189. ZHAO L, Yang J, Chen M, Xiang X, et al
    Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
    Ann Hematol. 2024 Feb 8. doi: 10.1007/s00277-024-05646.
    PubMed     Abstract available


  190. FONTANA D, Zambrotta GPM, Scannella A, Piazza R, et al
    Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.
    Ann Hematol. 2024 Feb 7. doi: 10.1007/s00277-024-05649.
    PubMed     Abstract available


  191. SCHLOSSER P, Schiwitza A, Klaus J, Hieke-Schulz S, et al
    Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia.
    Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05627.
    PubMed     Abstract available


  192. SUAREZ EU, Piris MA, Rodriguez-Pinilla SM, Garcia JF, et al
    Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage.
    Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05647.
    PubMed    


  193. WANG J, Zhang H, Zhang R
    BRCA2 germline mutation in familial leukaemia with familial breast cancer: a case report.
    Ann Hematol. 2024;103:685-687.
    PubMed    


  194. BRUNNER A, Thalhammer-Thurner GC, Willenbacher W, Haun M, et al
    In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.
    Ann Hematol. 2024;103:553-563.
    PubMed     Abstract available


  195. FERNANDEZ-LUIS S, Gomez Lamas D, Cerezo Martin JM, Mora Barrios JM, et al
    Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age.
    Ann Hematol. 2024;103:583-591.
    PubMed     Abstract available


    January 2024
  196. CHEN Y, Pan M, Chen L, Peng M, et al
    Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
    Ann Hematol. 2024 Jan 31. doi: 10.1007/s00277-024-05629.
    PubMed     Abstract available


  197. CUI J, Zhao M, Liu W, Hong M, et al
    Effect of low skeletal muscle mass on NK cells in patients with acute myeloid leukemia and its correlation with prognosis.
    Ann Hematol. 2024 Jan 31. doi: 10.1007/s00277-024-05645.
    PubMed     Abstract available


  198. LIU Y, Ma Z
    Leukemia and mitophagy: a novel perspective for understanding oncogenesis and resistance.
    Ann Hematol. 2024 Jan 29. doi: 10.1007/s00277-024-05635.
    PubMed     Abstract available


  199. GABELLIER L, Peterlin P, Thepot S, Hicheri Y, et al
    Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
    Ann Hematol. 2024 Jan 26. doi: 10.1007/s00277-024-05623.
    PubMed     Abstract available


  200. CHATTOPADHYAY S, Lionel S, Selvarajan S, Devasia AJ, et al
    Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival.
    Ann Hematol. 2024 Jan 20. doi: 10.1007/s00277-024-05621.
    PubMed     Abstract available


  201. MURRU R, Galitzia A, Barabino L, Presicci R, et al
    Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis.
    Ann Hematol. 2024 Jan 18. doi: 10.1007/s00277-024-05625.
    PubMed     Abstract available


  202. ZHAO Y, Zhang X, Zhang M, Guo R, et al
    Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
    Ann Hematol. 2024 Jan 12. doi: 10.1007/s00277-024-05617.
    PubMed     Abstract available


  203. DEREME J, Voruz S, Solly F, Schoumans J, et al
    Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript.
    Ann Hematol. 2024 Jan 9. doi: 10.1007/s00277-023-05600.
    PubMed    


  204. SONG J, Li W, Bai Y, Zhou P, et al
    A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
    Ann Hematol. 2024 Jan 6. doi: 10.1007/s00277-023-05594.
    PubMed     Abstract available


  205. PERRUSO LL, Velloso E, Rocha V, Rego EM, et al
    Patterns and prognostic impact of CNS infiltration in adults with newly diagnosed acute lymphoblastic leukemia.
    Ann Hematol. 2024 Jan 5. doi: 10.1007/s00277-023-05609.
    PubMed     Abstract available


  206. WANG R, Xu Y, Wang B, Wang H, et al
    Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
    Ann Hematol. 2024;103:61-71.
    PubMed     Abstract available


  207. AL BARASHDI MAS, Ali A, McMullin MF, Mills K, et al
    CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy.
    Ann Hematol. 2024;103:73-88.
    PubMed     Abstract available


    December 2023
  208. HUANG P, Chang H, Zhang R, Wu Y, et al
    Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemia.
    Ann Hematol. 2023 Dec 28. doi: 10.1007/s00277-023-05593.
    PubMed     Abstract available


  209. PAN B, Xu Z, Du K, Gao R, et al
    Investigation of fatty acid metabolism in chronic lymphocytic leukemia to guide clinical outcome and therapy.
    Ann Hematol. 2023 Dec 27. doi: 10.1007/s00277-023-05590.
    PubMed     Abstract available


  210. SOBAS M, Knopinska-Posluszny W, Piatkowska-Jakubas B, Garcia-Alvarez F, et al
    Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
    Ann Hematol. 2023 Dec 19. doi: 10.1007/s00277-023-05582.
    PubMed     Abstract available


  211. PARK T, Byun JM, Shin DY, Koh Y, et al
    Clinical characteristics and treatment outcomes of Asian patients with T-cell large granular lymphocytic Leukemia: a single-center analysis of 67 cases.
    Ann Hematol. 2023 Dec 8. doi: 10.1007/s00277-023-05575.
    PubMed     Abstract available


  212. ZHENG X, Gao H, Lu N, Wang M, et al
    Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.
    Ann Hematol. 2023;102:3603-3611.
    PubMed     Abstract available


  213. HU J, Zhao J, Wang C, Jia M, et al
    Epstein-Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation.
    Ann Hematol. 2023;102:3593-3601.
    PubMed     Abstract available


  214. ANDERSEN M JR, Bindal P, Michaels P, Elavalakanar P, et al
    Clonal myeloid disorders following CAR T-cell therapy.
    Ann Hematol. 2023;102:3643-3645.
    PubMed    


  215. BEWERSDORF JP, Shallis RM, Sharon E, Park S, et al
    A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
    Ann Hematol. 2023 Dec 1. doi: 10.1007/s00277-023-05552.
    PubMed     Abstract available


    November 2023
  216. MARRA JD, Frioni F, Minnella G, Rossi M, et al
    Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management.
    Ann Hematol. 2023 Nov 29. doi: 10.1007/s00277-023-05561.
    PubMed    


  217. MULAS O, Abruzzese E, Luciano L, Iurlo A, et al
    The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
    Ann Hematol. 2023 Nov 28. doi: 10.1007/s00277-023-05556.
    PubMed     Abstract available


  218. ISHIDA H, Arakawa Y, Hasegawa D, Usami I, et al
    Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 25. doi: 10.1007/s00277-023-05557.
    PubMed     Abstract available


  219. FISCHER D, Toenges R, Kiil K, Michalik S, et al
    Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 24. doi: 10.1007/s00277-023-05495.
    PubMed     Abstract available


  220. SHANG CY, Bei LY, Wu JZ, Sheng HR, et al
    NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia.
    Ann Hematol. 2023 Nov 23. doi: 10.1007/s00277-023-05554.
    PubMed     Abstract available


  221. GAO J, Han S, Deng B, Deng Y, et al
    Research progress of additional pathogenic mutations in chronic neutrophilic leukemia.
    Ann Hematol. 2023 Nov 22. doi: 10.1007/s00277-023-05550.
    PubMed     Abstract available


  222. TIAN J, Wei A, Wang B, Yang J, et al
    Allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 22. doi: 10.1007/s00277-023-05506.
    PubMed     Abstract available


  223. LAP CJ, Abrahim MS, Nassereddine S
    Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.
    Ann Hematol. 2023 Nov 17. doi: 10.1007/s00277-023-05545.
    PubMed     Abstract available


  224. CHEN B, Zhao Y, Xu S, Jiang F, et al
    USF2 promotes autophagy and proliferation in chronic lymphocytic leukemia by inhibiting STUB1-induced NFAT5 ubiquitination.
    Ann Hematol. 2023 Nov 10. doi: 10.1007/s00277-023-05522.
    PubMed     Abstract available


  225. LUCIJANIC M, Tomasovic-Loncaric C, Stoos-Veic T, De Both T, et al
    Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05529.
    PubMed    


  226. AHMED HA, Nafady A, Ahmed EH, Hassan EEN, et al
    CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05540.
    PubMed     Abstract available


  227. FAN S, Wang L, Lu Y, Li Z, et al
    Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05519.
    PubMed     Abstract available


  228. DE OLIVEIRA FERNANDES JUNIOR I, Arcuri LJ
    Myeloablative or reduced-intensity/non-myeloablative hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in adults older than 40 years old - a secondary analysis of a CIBMTR database.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05532.
    PubMed     Abstract available


  229. BABAKHANLOU R, Nader ME, Alvarado Y
    Correction to: A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia.
    Ann Hematol. 2023 Nov 3. doi: 10.1007/s00277-023-05524.
    PubMed    


  230. HUSSAN SS, Ali MS, Fatima M, Altaf M, et al
    Epigenetically dysregulated NOTCH-Delta-HES signaling cascade can serve as a subtype classifier for acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 3. doi: 10.1007/s00277-023-05515.
    PubMed     Abstract available


  231. HUANG X, Li T, Zhang Y, Gao X, et al
    Hemophagocytosis by multinucleated leukemic blasts, basophilia, and micromegakaryocytes in AML with TLS::ERG.
    Ann Hematol. 2023;102:3279-3281.
    PubMed    


  232. PERRONE S, Imperatore S, Sucato G, Notarianni E, et al
    Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect.
    Ann Hematol. 2023;102:3025-3030.
    PubMed     Abstract available


  233. HEGDE NC, Kumar A, Kaundal S, Saha L, et al
    Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia.
    Ann Hematol. 2023;102:3125-3132.
    PubMed     Abstract available


    October 2023
  234. SAVANI S, Chennapragada SS, Ramphul K, Dandwani M, et al
    Factors associated with inpatient mortality during daunorubicin and cytarabine induction in adults with acute myeloid leukemia-a national inpatient sample analysis.
    Ann Hematol. 2023 Oct 27. doi: 10.1007/s00277-023-05505.
    PubMed    


  235. TANG H, Chen Y, Zhang N, Deng J, et al
    Higher expression of programmed cell death 4 (PDCD4) in acute myeloid leukemia is associated with better prognosis after chemotherapy.
    Ann Hematol. 2023 Oct 25. doi: 10.1007/s00277-023-05516.
    PubMed     Abstract available


  236. CUI Y, Peng H
    Imatinib and CAR T cell therapy enable sustained response in a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia.
    Ann Hematol. 2023 Oct 21. doi: 10.1007/s00277-023-05489.
    PubMed    


  237. FEI X, Zhang W, Gu J, Yang F, et al
    CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
    Ann Hematol. 2023 Oct 17. doi: 10.1007/s00277-023-05502.
    PubMed     Abstract available


  238. YIN S, Zheng X, Zhang W, Zhao H, et al
    Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
    Ann Hematol. 2023 Oct 16. doi: 10.1007/s00277-023-05486.
    PubMed     Abstract available


  239. EISENACH S, Zinke J, Bramer D, Hartinger S, et al
    Detection of a rare JAK2(exon13InDel)-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Loffler endocarditis.
    Ann Hematol. 2023 Oct 16. doi: 10.1007/s00277-023-05490.
    PubMed    


  240. CREMER A, Enssle JC, Pfaff S, Kouidri K, et al
    Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
    Ann Hematol. 2023;102:2903-2908.
    PubMed     Abstract available


  241. MARTINO G, Cimino G, Caridi M, Perta G, et al
    One disease, two faces: clonally-related AML and MPDCP with skin involvement.
    Ann Hematol. 2023;102:2969-2971.
    PubMed    


    September 2023
  242. XU Y, Gao H, Li H
    The gut microbiome: an important factor influencing therapy for pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2023 Sep 29. doi: 10.1007/s00277-023-05480.
    PubMed     Abstract available


  243. PEREIRA MP, Herrity E, Kim DDH
    TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
    Ann Hematol. 2023 Sep 28. doi: 10.1007/s00277-023-05462.
    PubMed     Abstract available


  244. ZOU D, Lv M, Chen Y, Niu T, et al
    Down-regulation of Musashi-2 exerts antileukemic effects on acute lymphoblastic leukemia cells and increases sensitivity to dexamethasone.
    Ann Hematol. 2023 Sep 26. doi: 10.1007/s00277-023-05468.
    PubMed     Abstract available


  245. CANDAN O, Demirtas D, Yanik AM, Atagunduz I, et al
    The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia.
    Ann Hematol. 2023 Sep 20. doi: 10.1007/s00277-023-05456.
    PubMed    


  246. LIN Q, Ye P, Wang T, Lu Y, et al
    Successful use of venetoclax combined with azacitidine in isolated extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a case report.
    Ann Hematol. 2023 Sep 20. doi: 10.1007/s00277-023-05401.
    PubMed    


  247. LI H, Hou J, Fu Y, Zhao Y, et al
    miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
    Ann Hematol. 2023 Sep 19. doi: 10.1007/s00277-023-05441.
    PubMed     Abstract available


  248. WENG G, Huang J, He X, Xue T, et al
    Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
    Ann Hematol. 2023 Sep 18. doi: 10.1007/s00277-023-05452.
    PubMed     Abstract available


  249. BABAKHANLOU R, Ellie-Nader M, Alvarado Y
    A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia.
    Ann Hematol. 2023 Sep 15. doi: 10.1007/s00277-023-05433.
    PubMed     Abstract available


  250. CROUCHER PJP, Ridinger M, Becker PS, Lin TL, et al
    Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2023 Sep 13. doi: 10.1007/s00277-023-05442.
    PubMed     Abstract available


  251. JIANG S, Lu X, Wei R, Zhang A, et al
    Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study.
    Ann Hematol. 2023 Sep 8. doi: 10.1007/s00277-023-05406.
    PubMed     Abstract available


  252. WANG Q, Liang Z, Ren H, Dong Y, et al
    Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2023 Sep 4. doi: 10.1007/s00277-023-05429.
    PubMed     Abstract available


  253. LIU Y, Chen P, Chen G, Chen X, et al
    E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.
    Ann Hematol. 2023 Sep 4. doi: 10.1007/s00277-023-05431.
    PubMed     Abstract available


  254. WANG S, Wang X, Shen K, Wei C, et al
    Insulin-like growth factor 1 receptor inhibits the proliferation of acute myeloid leukaemia cells via NK cell activation.
    Ann Hematol. 2023;102:2353-2364.
    PubMed     Abstract available


  255. LI VWK, Yim R, Lee P, Chin L, et al
    Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction.
    Ann Hematol. 2023;102:2517-2527.
    PubMed     Abstract available


    August 2023
  256. INFANTE J, Esteves G, Raposo J, de Lacerda JF, et al
    Predictors of very early death in acute promyelocytic leukemia: a retrospective real-world cohort study.
    Ann Hematol. 2023 Aug 31. doi: 10.1007/s00277-023-05422.
    PubMed     Abstract available


  257. KIMURA H, Onozawa M, Yoshida S, Miyashita N, et al
    Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2023 Aug 19. doi: 10.1007/s00277-023-05405.
    PubMed     Abstract available


  258. ISFORT S, Manz K, Teichmann LL, Crysandt M, et al
    Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
    Ann Hematol. 2023 Aug 18. doi: 10.1007/s00277-023-05394.
    PubMed     Abstract available


  259. CORBINGI A, Putzulu R, Massini G, Colangelo M, et al
    Genetic mutations and leukapheresis in acute myeloid leukemia: is there a link?
    Ann Hematol. 2023 Aug 17. doi: 10.1007/s00277-023-05414.
    PubMed     Abstract available


  260. QI F, Bao M, Gao H, Zhang X, et al
    Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.
    Ann Hematol. 2023 Aug 14. doi: 10.1007/s00277-023-05413.
    PubMed     Abstract available


  261. DUAN W, Yang S, Zhao T, Hu L, et al
    Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
    Ann Hematol. 2023 Aug 12. doi: 10.1007/s00277-023-05400.
    PubMed     Abstract available


  262. BORAH P, Dayal N, Pathak S, Naithani R, et al
    Daratumumab-a novel treatment strategy in relapsed/refractory acute leukemia.
    Ann Hematol. 2023 Aug 9. doi: 10.1007/s00277-023-05404.
    PubMed    


  263. LIU K, Shao J, Cai J, Tang J, et al
    Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children's Cancer Group study ALL-2015.
    Ann Hematol. 2023 Aug 8. doi: 10.1007/s00277-023-05389.
    PubMed     Abstract available


  264. FRACCAROLI A, Vogt D, Rothmayer M, Spiekermann K, et al
    Impact of extramedullary disease in AML patients undergoing sequential RIC for HLA-matched transplantation: occurrence, risk factors, relapse patterns, and outcome.
    Ann Hematol. 2023;102:2213-2223.
    PubMed     Abstract available


  265. LOSCOCCO GG, Vannucchi AM
    Myeloid sarcoma: more and less than a distinct entity.
    Ann Hematol. 2023;102:1973-1984.
    PubMed     Abstract available


  266. LUBKE J, Naumann N, Metzgeroth G, Kreil S, et al
    Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.
    Ann Hematol. 2023;102:2077-2085.
    PubMed     Abstract available


  267. RAHMATI A, Mafi A, Vakili O, Soleymani F, et al
    Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways.
    Ann Hematol. 2023 Aug 1. doi: 10.1007/s00277-023-05383.
    PubMed     Abstract available


    July 2023
  268. GAO J, Gao J, Min F
    Chronic neutrophilic leukemia with JAK2 mutation: is it true chronic neutrophilic leukemia?
    Ann Hematol. 2023 Jul 31. doi: 10.1007/s00277-023-05376.
    PubMed    


  269. STADLER M, Hambach L, Dammann E, Diedrich H, et al
    The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease.
    Ann Hematol. 2023 Jul 25. doi: 10.1007/s00277-023-05276.
    PubMed     Abstract available


  270. ARAIE H, Arai Y, Kida M, Aoki J, et al
    Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy.
    Ann Hematol. 2023 Jul 21. doi: 10.1007/s00277-023-05356.
    PubMed     Abstract available


  271. NIU D, Zhao Y, Wang J, Ye E, et al
    Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years.
    Ann Hematol. 2023 Jul 19. doi: 10.1007/s00277-023-05372.
    PubMed     Abstract available


  272. ZHANG Q, Yan H, Ren X, Liu L, et al
    Platelet is an unfavorable prognostic biomarker and associated with leukemia stem cells and immunomodulatory factors in acute myeloid leukemia.
    Ann Hematol. 2023 Jul 15. doi: 10.1007/s00277-023-05367.
    PubMed     Abstract available


  273. ZHOU M, Zhong G, Yu Y, Wang R, et al
    Successful treatment of systemic mastocytosis with acute myeloid leukemia: a case report.
    Ann Hematol. 2023 Jul 11. doi: 10.1007/s00277-023-05341.
    PubMed    


  274. POHLMANN A, Bentgens E, Schulke C, Kuron D, et al
    Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML).
    Ann Hematol. 2023 Jul 10. doi: 10.1007/s00277-023-05353.
    PubMed     Abstract available


  275. SHEN YJ, Zhang Y, Chang J, Wang HF, et al
    CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
    Ann Hematol. 2023;102:1731-1738.
    PubMed     Abstract available


  276. YANG S, Li N, Zhu R, Feng Y, et al
    Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia.
    Ann Hematol. 2023 Jul 1. doi: 10.1007/s00277-023-05309.
    PubMed     Abstract available


  277. SOBON A, Drozd-Sokolowska J, Paszkiewicz-Kozik E, Poplawska L, et al
    Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.
    Ann Hematol. 2023 Jul 1. doi: 10.1007/s00277-023-05304.
    PubMed     Abstract available


    June 2023
  278. VON TRESCKOW J, Heyl N, Robrecht S, Giza A, et al
    Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
    Ann Hematol. 2023 Jun 26. doi: 10.1007/s00277-023-05314.
    PubMed     Abstract available


  279. GRUBER I, Koelbl O, Treutwein M, Zeman F, et al
    Analysis of long-term mortality after total body irradiation-based and melphalan-based chemotherapy conditioning for acute myeloid leukemia.
    Ann Hematol. 2023 Jun 22. doi: 10.1007/s00277-023-05318.
    PubMed     Abstract available


  280. YU WJ, Sun YQ, Xu LP, Zhang XH, et al
    Comparison of outcomes for patients with acute myeloid leukemia undergoing haploidentical stem cell transplantation in first and second complete remission.
    Ann Hematol. 2023 Jun 21. doi: 10.1007/s00277-023-05324.
    PubMed     Abstract available


  281. ZEIDAN AM, Pollyea DA, Borate U, Vasconcelos A, et al
    Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
    Ann Hematol. 2023 Jun 21. doi: 10.1007/s00277-023-05327.
    PubMed    


  282. R C, Malik PS, Sahoo RK, Sharawat S, et al
    Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.
    Ann Hematol. 2023 Jun 15. doi: 10.1007/s00277-023-05280.
    PubMed     Abstract available


  283. TANG X, Wang Y, Zhu Y, Guo Y, et al
    Basic mechanisms and novel potential therapeutic targets for ferroptosis in acute myeloid leukemia.
    Ann Hematol. 2023 Jun 14. doi: 10.1007/s00277-023-05293.
    PubMed     Abstract available


  284. YU Z, Yao Y, Zhang Y, Chen J, et al
    The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2023 Jun 10. doi: 10.1007/s00277-023-05313.
    PubMed    


  285. ZANELLI M, Sanguedolce F, Zizzo M, Palicelli A, et al
    Mast cell leukemia associated with essential thrombocythemia: a type of MCL-AHN (MCL-AMN).
    Ann Hematol. 2023 Jun 8. doi: 10.1007/s00277-023-05310.
    PubMed    


  286. CANNAS G, Poutrel S, Heiblig M, Labussiere H, et al
    Sickle cell disease and acute leukemia: one case report and an extensive review.
    Ann Hematol. 2023 Jun 3:1-11. doi: 10.1007/s00277-023-05294.
    PubMed     Abstract available


  287. GEELEN IGP, Gullaksen SE, Ilander MM, Olssen-Stromberg U, et al
    Switching from imatinib to nilotinib plus pegylated interferon-alpha2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
    Ann Hematol. 2023;102:1395-1408.
    PubMed     Abstract available


  288. DESPREZ C, Kouatchet A, Marchand T, Mear JB, et al
    Outcome of patients with newly diagnosed AML admitted to the ICU, including preemptive admission - a multi-center study.
    Ann Hematol. 2023;102:1383-1393.
    PubMed     Abstract available


    May 2023
  289. JEONG D, Gu JY, Seo MS, Lee JS, et al
    A case of donor cell leukemia driven by a de novo NRAS mutation with complex karyotype.
    Ann Hematol. 2023 May 31. doi: 10.1007/s00277-023-05291.
    PubMed    


  290. TSILIMIDOS G, Blum S
    Comment on: JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.
    Ann Hematol. 2023 May 31. doi: 10.1007/s00277-023-05297.
    PubMed    


  291. HUANG YH, Wan CL, Dai HP, Xue SL, et al
    Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
    Ann Hematol. 2023 May 25. doi: 10.1007/s00277-023-05286.
    PubMed     Abstract available


  292. CAI M, Liu X, Luo A, Yang X, et al
    ADAR1 polymorphisms contribute to increased susceptibility in pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2023 May 22. doi: 10.1007/s00277-023-05285.
    PubMed     Abstract available


  293. HAILU S, Kinde S, Cross M, Tsegaye A, et al
    Estimating prognostic relevant cutoff values for a multiplex PCR detecting BCR::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings.
    Ann Hematol. 2023 May 22. doi: 10.1007/s00277-023-05254.
    PubMed     Abstract available


  294. HU M, Liu R, Li J, Zhang L, et al
    Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series.
    Ann Hematol. 2023 May 20:1-13. doi: 10.1007/s00277-023-05245.
    PubMed     Abstract available


  295. LUO JS, Zhang XL, Huang DP, Chen YQ, et al
    Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.
    Ann Hematol. 2023 May 18. doi: 10.1007/s00277-023-05270.
    PubMed     Abstract available


  296. ZHANG Q, Huang MJ, Wang HY, Wu Y, et al
    A novel prognostic nomogram for adult acute lymphoblastic leukemia: a comprehensive analysis of 321 patients.
    Ann Hematol. 2023 May 13. doi: 10.1007/s00277-023-05267.
    PubMed     Abstract available


  297. LV XY, Li ZJ
    Reduced plasma coagulation factor XIII in patients with acute leukemia in remission during consolidation chemotherapy cycles.
    Ann Hematol. 2023 May 9. doi: 10.1007/s00277-023-05261.
    PubMed     Abstract available


  298. FERREIRA APS, Seguro FS, Abdo ARN, Santos FM, et al
    Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response.
    Ann Hematol. 2023 May 9. doi: 10.1007/s00277-023-05242.
    PubMed    


  299. SRINIVASAN S, Ramanathan S, Kumar S, Peyam S, et al
    Prevalence and prognostic significance of IKZF1 deletion in paediatric acute lymphoblastic leukemia: A systematic review and meta-analysis.
    Ann Hematol. 2023 May 8. doi: 10.1007/s00277-023-05250.
    PubMed     Abstract available


  300. ARAIE H, Tasaki T, Hosono N, Tsujikawa T, et al
    Hematopoietic status of the whole-body bone marrow in hypoplastic acute promyelocytic leukemia as evaluated by (18)F-FLT PET/MRI.
    Ann Hematol. 2023 May 8. doi: 10.1007/s00277-023-05224.
    PubMed    


  301. ASHOUB MH, Naseri A, Mohammadi P, Mohammadi M, et al
    Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis.
    Ann Hematol. 2023 May 3. doi: 10.1007/s00277-023-05246.
    PubMed     Abstract available


  302. ALGHANDOUR R, Sakr DH, Shaaban Y
    Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.
    Ann Hematol. 2023 May 2. doi: 10.1007/s00277-023-05241.
    PubMed     Abstract available


  303. PAN Z, Wang L, Fu W, Jiang C, et al
    Pediatric chemotherapy versus allo-HSCT for adolescent and adult Philadelphia chromosome-negative ALL in first complete remission: a meta-analysis.
    Ann Hematol. 2023;102:1131-1140.
    PubMed     Abstract available


  304. KOSCHADE SE, Stratmann JA, Zeiner PS, Finkelmeier F, et al
    Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience.
    Ann Hematol. 2023;102:1045-1052.
    PubMed     Abstract available


  305. ARMSTRONG C, Au WY, Ma ESK, Wong SHM, et al
    Sustained spontaneous remission in KMT2A-MLLT3 mutated myeloid sarcoma.
    Ann Hematol. 2023;102:1271-1274.
    PubMed    


  306. XIE W, Liang Z, Wang Q, Wang B, et al
    An adult case of systemic lupus erythematosus and cerebral vasculitis after umbilical cord blood transplantation for acute myeloid leukemia.
    Ann Hematol. 2023 May 1. doi: 10.1007/s00277-023-05229.
    PubMed    


  307. YAMASAKI S, Mizuno S, Iwasaki M, Seo S, et al
    Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics.
    Ann Hematol. 2023 May 1. doi: 10.1007/s00277-023-05243.
    PubMed     Abstract available


    April 2023
  308. TAN KW, Zhu YY, Qiu QC, Wang M, et al
    Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
    Ann Hematol. 2023 Apr 27. doi: 10.1007/s00277-023-05236.
    PubMed     Abstract available


  309. YIGIT KAYA S, Bektas S, Askin AE, Balik Aydin B, et al
    Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient.
    Ann Hematol. 2023 Apr 26. doi: 10.1007/s00277-023-05231.
    PubMed    


  310. LUCIANO L, Latagliata R, Gugliotta G, Annunziata M, et al
    Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
    Ann Hematol. 2023 Apr 20. doi: 10.1007/s00277-023-05159.
    PubMed     Abstract available


  311. DUDA K, Wieczorkiewicz-Kabut A, Koclega A, Zielinska P, et al
    Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience.
    Ann Hematol. 2023 Apr 19. doi: 10.1007/s00277-023-05226.
    PubMed     Abstract available


  312. MASETTI R, Muratore E, Gori D, Prete A, et al
    Response to: meta-analysis on allogeneic transplant for treating pediatric patients with acute myeloid leukemia in first remission: reanalysis of primary data.
    Ann Hematol. 2023 Apr 15. doi: 10.1007/s00277-023-05219.
    PubMed    


  313. FERREIRA APS, Seguro FS, Abdo ARN, Santos FM, et al
    Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
    Ann Hematol. 2023 Apr 13. doi: 10.1007/s00277-023-05189.
    PubMed     Abstract available


  314. CHEN K, Hendrie PC, Naresh KN
    Aleukemic mast cell leukemia, well-differentiated and chronic type.
    Ann Hematol. 2023 Apr 4. doi: 10.1007/s00277-023-05195.
    PubMed    


  315. HAUPTMANN L, Midic D, Eigendorff F, Malouhi A, et al
    Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia.
    Ann Hematol. 2023 Apr 4. doi: 10.1007/s00277-023-05208.
    PubMed    


  316. PERRONE S, Capria S, Bernardi M, Marchesi F, et al
    Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients.
    Ann Hematol. 2023;102:769-775.
    PubMed     Abstract available


  317. BACCELLI F, Leardini D, Cerasi S, Messelodi D, et al
    ERCC6L2-related disease: a novel entity of bone marrow failure disorder with high risk of clonal evolution.
    Ann Hematol. 2023;102:699-705.
    PubMed     Abstract available


  318. KURON D, Pohlmann A, Angenendt L, Kessler T, et al
    Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.
    Ann Hematol. 2023;102:755-760.
    PubMed     Abstract available


    March 2023
  319. GANDO Y, Yasu T
    Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia.
    Ann Hematol. 2023 Mar 29. doi: 10.1007/s00277-023-05201.
    PubMed    


  320. LAZZAROTTO D, Tanasi I, Vitale A, Piccini M, et al
    Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation:
    Ann Hematol. 2023 Mar 24. doi: 10.1007/s00277-023-05162.
    PubMed     Abstract available


  321. ZHUANG H, Li F, Xu Y, Pei R, et al
    Loss of IRF8 inhibits the growth of acute myeloid leukemia cells.
    Ann Hematol. 2023 Mar 23. doi: 10.1007/s00277-023-05156.
    PubMed     Abstract available


  322. TOSONI L, Fabbro D, Pizzano U, Mullai R, et al
    JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.
    Ann Hematol. 2023 Mar 22. doi: 10.1007/s00277-023-05187.
    PubMed    


  323. LIANG X, Fu W, Peng Y, Duan J, et al
    Lycorine induces apoptosis of acute myeloid leukemia cells and inhibits triglyceride production via binding and targeting FABP5.
    Ann Hematol. 2023 Mar 21. doi: 10.1007/s00277-023-05169.
    PubMed     Abstract available


  324. ITONAGA H, Miyazaki Y, Aoki K, Shingai N, et al
    Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database.
    Ann Hematol. 2023 Mar 15. doi: 10.1007/s00277-023-05167.
    PubMed     Abstract available


  325. SHARMA A, Yang J, Singh V
    Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States.
    Ann Hematol. 2023 Mar 14. doi: 10.1007/s00277-023-05154.
    PubMed     Abstract available


  326. BRECCIA M, Olimpieri PP, Celant S, Olimpieri OM, et al
    Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA).
    Ann Hematol. 2023 Mar 13. doi: 10.1007/s00277-023-05168.
    PubMed    


  327. HELLOU T, Cohen O, Avigdor A, Amitai I, et al
    The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival.
    Ann Hematol. 2023 Mar 11. doi: 10.1007/s00277-023-05158.
    PubMed     Abstract available


  328. FERRARI LC, Rivas MM, Navickas AB, Dick H, et al
    PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
    Ann Hematol. 2023 Mar 9. doi: 10.1007/s00277-023-05151.
    PubMed     Abstract available


  329. CHANG J, Shen YJ, Shi T, Wang HF, et al
    Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ann Hematol. 2023 Mar 9. doi: 10.1007/s00277-023-05127.
    PubMed    


  330. VAN DER ZOUWEN B, Koster EAS, von dem Borne PA, Oosten LEM, et al
    Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients.
    Ann Hematol. 2023 Mar 7. doi: 10.1007/s00277-023-05145.
    PubMed     Abstract available


  331. MESSORI A, Hyeraci G
    Meta-analysis on allogeneic transplant for treating pediatric patients with acute myeloid leukemia in first remission: reanalysis of primary data.
    Ann Hematol. 2023 Mar 6. doi: 10.1007/s00277-023-05101.
    PubMed    


  332. REED DR, Wooster M, Isom S, Ellis LR, et al
    Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen.
    Ann Hematol. 2023 Mar 1. doi: 10.1007/s00277-023-05141.
    PubMed     Abstract available


  333. MAO S, Qian Y, Wei W, Lin X, et al
    FLOT1 knockdown inhibits growth of AML cells through triggering apoptosis and pyroptosis.
    Ann Hematol. 2023;102:583-595.
    PubMed     Abstract available


  334. NIEDERWIESER D, Lang T, Krahl R, Heinicke T, et al
    Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
    Ann Hematol. 2023;102:547-561.
    PubMed     Abstract available


  335. PARK W, Byun JM, Hong J, Kim I, et al
    Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation.
    Ann Hematol. 2023;102:629-639.
    PubMed     Abstract available


    February 2023
  336. SIMKOVIC M, Turcsanyi P, Spacek M, Mihalyova J, et al
    COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
    Ann Hematol. 2023 Feb 27:1-7. doi: 10.1007/s00277-023-05147.
    PubMed     Abstract available


  337. MATSUDA K, Yoshida T, Sugimoto K
    High susceptibility of febrile neutropenia in Japanese patients receiving venetoclax plus azacitidine therapy for acute myeloid leukemia.
    Ann Hematol. 2023 Feb 23. doi: 10.1007/s00277-023-05143.
    PubMed    


  338. AMMAD UD DIN M, Mahmud A, Mostafa M, Shahzad M, et al
    Risks and outcomes of hospitalizations in patients with chronic lymphocytic leukemia admitted with immune thrombocytopenia: an analysis of the National Inpatient Sample Database.
    Ann Hematol. 2023 Feb 13. doi: 10.1007/s00277-023-05133.
    PubMed     Abstract available


  339. CERRANO M, Chevret S, Raffoux E, Rabian F, et al
    Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis.
    Ann Hematol. 2023 Feb 11:1-8. doi: 10.1007/s00277-023-05119.
    PubMed     Abstract available


  340. YUE K, Gao H, Liang S, Wu N, et al
    Improved Vdelta2(+) T cells recovery correlates to reduced incidences of mortality and relapse in acute myeloid leukemia after hematopoietic transplantation.
    Ann Hematol. 2023 Feb 10. doi: 10.1007/s00277-023-05125.
    PubMed     Abstract available


  341. LI S, Gao Y, Li F, Zheng Y, et al
    Value of the FDP/FIB ratio in predicting early severe bleeding events in patients with newly diagnosed acute promyelocytic leukemia.
    Ann Hematol. 2023 Feb 7. doi: 10.1007/s00277-023-05122.
    PubMed     Abstract available


  342. ZHANG R, Liu Y, Song H, Tan Y, et al
    Clonal evolution analysis of a rare acute promyelocytic leukemia patient transforming from essential thrombocythemia.
    Ann Hematol. 2023 Feb 7. doi: 10.1007/s00277-023-05112.
    PubMed    


  343. ZHANG T, Zhou H, Xu M, Qian C, et al
    Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia.
    Ann Hematol. 2023 Feb 6. doi: 10.1007/s00277-023-05110.
    PubMed    


  344. SUN Y, Wang Q, Zhang X, Zhang Z, et al
    Molecular genetics and management of world health organization defined atypical chronic myeloid leukemia.
    Ann Hematol. 2023 Feb 3. doi: 10.1007/s00277-023-05106.
    PubMed     Abstract available


  345. ZEIDAN AM, Pollyea DA, Borate U, Vasconcelos A, et al
    Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
    Ann Hematol. 2023 Feb 3. doi: 10.1007/s00277-023-05109.
    PubMed     Abstract available


  346. DE LA GARZA-SALAZAR F, Gomez-De Leon A, Gomez-Almaguer D, Colunga-Pedraza PR, et al
    Vinblastine as a bridge to 7 + 3 in acute myeloid leukaemia.
    Ann Hematol. 2023;102:487-489.
    PubMed    


  347. KLEMENT P, Fiedler W, Gabdoulline R, Dallmann LK, et al
    Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
    Ann Hematol. 2023;102:323-328.
    PubMed     Abstract available


  348. KUNDU R, Seeger R, Elfassy MD, Rozenberg D, et al
    The association between nutritional risk index and ICU outcomes across hematologic malignancy patients with acute respiratory failure.
    Ann Hematol. 2023;102:439-445.
    PubMed     Abstract available


  349. HUANG J, Zhu Y, Li J, Yang G, et al
    The KMT2A rearrangement is an early event prior to KMT2A-PTD in AML patients with both molecular aberrations.
    Ann Hematol. 2023;102:495-497.
    PubMed    



  350. ACUTE LEUKEMIAS XVIII Biology and Treatment Strategies.
    Ann Hematol. 2023;102.
    PubMed    


    January 2023
  351. STANULLA M, Schewe DM, Bornhauser B, Bourquin JP, et al
    Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia.
    Ann Hematol. 2023 Jan 18. doi: 10.1007/s00277-023-05083.
    PubMed    


  352. AIBA M, Shigematsu A, Suzuki T, Miyagishima T, et al
    Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia.
    Ann Hematol. 2023 Jan 16. doi: 10.1007/s00277-023-05102.
    PubMed     Abstract available


  353. CHEUNG CYM, Leung RYY, Tam AR, Sim JPY, et al
    Disseminated Mycobacterium haemophilum infection during alemtuzumab treatment of T-cell prolymphocytic leukemia.
    Ann Hematol. 2023 Jan 13. doi: 10.1007/s00277-022-05053.
    PubMed    


  354. FU W, Hu Y, Lu G, Xu L, et al
    Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment.
    Ann Hematol. 2023 Jan 12. doi: 10.1007/s00277-023-05096.
    PubMed     Abstract available


  355. CAO HY, Wan CL, Xue SL
    Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis.
    Ann Hematol. 2023;102:155-165.
    PubMed     Abstract available


  356. HUANG W, Xue S, Zhang Y, Liu F, et al
    Refractory hepatosplenic T-cell lymphoma was successfully treated with salvage allogeneic hematopoietic stem cell transplantation combined with enhanced myeloablative preconditioning.
    Ann Hematol. 2023;102:175-180.
    PubMed     Abstract available


  357. KATAMESH B, Nanaa A, He R, Viswanatha D, et al
    Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms.
    Ann Hematol. 2023;102:211-212.
    PubMed    


    December 2022
  358. LI R, Wang Z, Zhang Y, Guo M, et al
    Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2022 Dec 21. doi: 10.1007/s00277-022-05061.
    PubMed     Abstract available


  359. CELLINI A, Scarmozzino F, Friziero A, Trimarco V, et al
    Persistent splenomegaly due to littoral cell angiomatosis in venetoclax-induced undetectable minimal residual disease of chronic lymphocytic leukemia.
    Ann Hematol. 2022 Dec 21. doi: 10.1007/s00277-022-05067.
    PubMed    


  360. THAKRAL D, Singh VK, Gupta R, Jha N, et al
    Integrated single-cell transcriptome analysis of CD34 + enriched leukemic stem cells revealed intra- and inter-patient transcriptional heterogeneity in pediatric acute myeloid leukemia.
    Ann Hematol. 2022 Dec 17. doi: 10.1007/s00277-022-05021.
    PubMed     Abstract available


  361. KONRAT J, Rosler W, Roiss M, Meier-Abt F, et al
    BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2.
    Ann Hematol. 2022 Dec 10:1-4. doi: 10.1007/s00277-022-05026.
    PubMed     Abstract available


  362. YANG TT, Song XL, Zhao YM, Ye BD, et al
    Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
    Ann Hematol. 2022;101:2731-2741.
    PubMed     Abstract available


  363. DIAMANTOPOULOS PT, Kontandreopoulou CN, Stafylidis C, Vlachopoulou D, et al
    Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
    Ann Hematol. 2022;101:2711-2717.
    PubMed     Abstract available


  364. ZHANG JY, Li Y, Ma YS, Sun XJ, et al
    Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases.
    Ann Hematol. 2022;101:2617-2625.
    PubMed     Abstract available


  365. NAJIMA Y, Tachibana T, Takeda Y, Koda Y, et al
    Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study.
    Ann Hematol. 2022;101:2719-2729.
    PubMed     Abstract available


  366. TAN X, Yuan H, Li D, Sun X, et al
    Clinical and prognostic role of 2-[(18)F]FDG PET/CT and sarcopenia in treatment-naive patients with T-cell lymphoblastic lymphoma.
    Ann Hematol. 2022;101:2699-2709.
    PubMed     Abstract available


    November 2022
  367. SULEMAN A, Tsui H, Ghorab Z, Lam PW, et al
    EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia.
    Ann Hematol. 2022 Nov 28. doi: 10.1007/s00277-022-05060.
    PubMed    


  368. SUN H, Yan H, Yan Z, Zhu Y, et al
    Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT.
    Ann Hematol. 2022 Nov 24. doi: 10.1007/s00277-022-05047.
    PubMed    


  369. BERDEL AF, Koch R, Gerss J, Hentrich M, et al
    A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
    Ann Hematol. 2022 Nov 18. pii: 10.1007/s00277-022-05025.
    PubMed     Abstract available


  370. ZHANG YW, Su L, Tan YH, Lin H, et al
    Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Ann Hematol. 2022 Nov 15. pii: 10.1007/s00277-022-05033.
    PubMed     Abstract available


  371. DELEHAYE F, Rouger J, Brossier D, Suttorp M, et al
    Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course.
    Ann Hematol. 2022 Nov 12. pii: 10.1007/s00277-022-05024.
    PubMed     Abstract available


  372. WELLER MC, Haralambieva E, Buhler MM, Benz R, et al
    CALR loss-of-heterozygosity as a potential driver for extramedullary AML.
    Ann Hematol. 2022;101:2571-2573.
    PubMed    


  373. ZHU Y, Dai Y, Tang X
    Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.
    Ann Hematol. 2022;101:2525-2528.
    PubMed    


    October 2022
  374. CORDELLA S, Parisotto A, Bettelli F, Morselli M, et al
    Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience.
    Ann Hematol. 2022 Oct 20. pii: 10.1007/s00277-022-05013.
    PubMed    


  375. PARK HS, Kim HK, Kim HS, Yang Y, et al
    The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications.
    Ann Hematol. 2022 Oct 12. pii: 10.1007/s00277-022-05002.
    PubMed     Abstract available


  376. TRIGUERO A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, et al
    Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
    Ann Hematol. 2022;101:2231-2239.
    PubMed     Abstract available


  377. LIN SC, Yao CY, Hsu CA, Lin CT, et al
    Functional association of NR4A3 downregulation with impaired differentiation in myeloid leukemogenesis.
    Ann Hematol. 2022;101:2209-2218.
    PubMed     Abstract available


  378. WATANABE N, Takaku T, Fujioka I, Tsuchiya S, et al
    Bosutinib-induced late-onset severe liver injury preceded by eosinophilia.
    Ann Hematol. 2022;101:2257-2262.
    PubMed     Abstract available


  379. ZHANG H, Zhan Q, Wang X, Gao F, et al
    TLS/FUS-ERG fusion gene in acute leukemia and myelodysplastic syndrome evolved to acute leukemia: report of six cases and a literature review.
    Ann Hematol. 2022 Oct 1. pii: 10.1007/s00277-022-04979.
    PubMed     Abstract available


    September 2022
  380. SPATH C, Schonau M, Gaubert S, Neumann T, et al
    Rhabdomyolysis induced by nelarabine.
    Ann Hematol. 2022;101:2111-2112.
    PubMed    


    August 2022
  381. HARADA N, Makuuchi Y, Kuno M, Takakuwa T, et al
    Intramural esophageal hematoma precipitated by acquired factor XI deficiency in a patient with relapsed T cell prolymphocytic leukemia after allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2022 Aug 31. pii: 10.1007/s00277-022-04970.
    PubMed    


  382. SAUGUES S, Lambert C, Daguenet E, Ansah HJ, et al
    Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
    Ann Hematol. 2022 Aug 30. pii: 10.1007/s00277-022-04955.
    PubMed     Abstract available


  383. MASETTI R, Muratore E, Gori D, Prete A, et al
    Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis.
    Ann Hematol. 2022 Aug 30. pii: 10.1007/s00277-022-04965.
    PubMed     Abstract available


  384. LUNA A, Perez-Lamas L, Boque C, Giraldo P, et al
    Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
    Ann Hematol. 2022 Aug 23. pii: 10.1007/s00277-022-04932.
    PubMed     Abstract available


  385. GIAMMARCO S, Bellesi S, Metafuni E, Rossi M, et al
    Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation.
    Ann Hematol. 2022 Aug 22. pii: 10.1007/s00277-022-04962.
    PubMed    


  386. YANADA M
    Treatment for relapsed acute promyelocytic leukemia.
    Ann Hematol. 2022 Aug 16. pii: 10.1007/s00277-022-04954.
    PubMed     Abstract available


  387. ZHAI Y, Shang J, Yao W, Wu D, et al
    Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.
    Ann Hematol. 2022 Aug 15. pii: 10.1007/s00277-022-04942.
    PubMed    


  388. CHIRICHES C, Khan D, Wieske M, Guillen N, et al
    Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
    Ann Hematol. 2022 Aug 8. pii: 10.1007/s00277-022-04905.
    PubMed     Abstract available


  389. BOEREKAMPS A, Hamberg P, Libourel EJ
    Discontinuation of azacitidine in acute myeloid leukemia: a feasible option?
    Ann Hematol. 2022 Aug 4. pii: 10.1007/s00277-022-04939.
    PubMed    


  390. DONG T, Wu N, Gao H, Liang S, et al
    CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vdelta2(+) T cell cytotoxicity.
    Ann Hematol. 2022 Aug 3. pii: 10.1007/s00277-022-04930.
    PubMed     Abstract available


  391. ROTTERDAM J, Thiaucourt M, Weiss C, Schwaab J, et al
    Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases.
    Ann Hematol. 2022;101:1825-1834.
    PubMed     Abstract available


  392. WANG W, Zhang Y, Zhao D, Zhang W, et al
    Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.
    Ann Hematol. 2022;101:1869-1872.
    PubMed    


    July 2022
  393. AHMED MZ, Venkatadasari I, Dyer S, Wall K, et al
    Clonal evolution in adult TCF3::HLF-positive acute lymphoblastic leukemia undergoing stem cell transplantation.
    Ann Hematol. 2022 Jul 30. pii: 10.1007/s00277-022-04941.
    PubMed    


  394. SEVINDIK OG, Mergen M, Mergen S, Mutlu YG, et al
    To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission.
    Ann Hematol. 2022 Jul 29. pii: 10.1007/s00277-022-04938.
    PubMed    


  395. SHIMONY S, Canaani J, Kugler E, Nachmias B, et al
    Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a realworld, multicenter, matched analysis.
    Ann Hematol. 2022 Jul 23. pii: 10.1007/s00277-022-04929.
    PubMed    


  396. SHIN WY, Kim JA, Yoon SY, Bang HI, et al
    Co-existence of a novel translocation t(11;22)(q23;q12.1) with PML-RARA in acute promyelocytic leukemia: a case report.
    Ann Hematol. 2022 Jul 2. pii: 10.1007/s00277-022-04911.
    PubMed    


  397. WU X, Cheng L, Liu X, Sun Y, et al
    Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.
    Ann Hematol. 2022;101:1493-1498.
    PubMed     Abstract available


  398. HIRANO M, Tamba M, Inoue N, Ikegami M, et al
    Durable response of therapy-related MDS/AML with concomitant Waldenstrom's macroglobulinemia treated with venetoclax and azacitidine.
    Ann Hematol. 2022;101:1587-1589.
    PubMed    


    June 2022
  399. YIN J, Zhu F, Zhang ZB, Wang Q, et al
    Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation.
    Ann Hematol. 2022 Jun 29. pii: 10.1007/s00277-022-04897.
    PubMed    


  400. SHIMONY S, Canaani J, Kugler E, Nachmias B, et al
    Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
    Ann Hematol. 2022 Jun 24. pii: 10.1007/s00277-022-04895.
    PubMed     Abstract available


  401. WOLACH O, Frisch A, Shargian L, Yeshurun M, et al
    Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.
    Ann Hematol. 2022 Jun 23. pii: 10.1007/s00277-022-04883.
    PubMed     Abstract available


  402. KATHPALIA M, Mishra P, Bajpai R, Bhurani D, et al
    Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2022 Jun 21. pii: 10.1007/s00277-022-04880.
    PubMed     Abstract available


  403. YANG X, Zhang R, Zhang Z
    The rare IRF2BP2-RARA fusion in acute promyelocytic leukemia.
    Ann Hematol. 2022 Jun 15. pii: 10.1007/s00277-022-04874.
    PubMed    


  404. BRAITSCH K, Schwarz A, Koch K, Hubbuch M, et al
    Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
    Ann Hematol. 2022;101:1311-1319.
    PubMed     Abstract available


  405. WATTEBLED KJ, Drumez E, Coiteux V, Magro L, et al
    Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2022;101:1321-1331.
    PubMed     Abstract available


  406. LEUNG WY, Cheuk DK, Cheng FW, Leung AW, et al
    Outcome prediction of chronic myeloid leukemia (CML) in children.
    Ann Hematol. 2022 Jun 1. pii: 10.1007/s00277-022-04852.
    PubMed     Abstract available


    May 2022
  407. OCHS MA, Marini BL, Perissinotti AJ, Foucar CE, et al
    Oncology stewardship in acute myeloid leukemia.
    Ann Hematol. 2022 May 26. pii: 10.1007/s00277-022-04872.
    PubMed     Abstract available


  408. SAITO K, Ichikawa S, Ohtomo R, Hatta S, et al
    Severe platelet transfusion refractoriness due to anti-HPA-5a antibody during induction chemotherapy for acute promyelocytic leukemia.
    Ann Hematol. 2022 May 25. pii: 10.1007/s00277-022-04875.
    PubMed    


  409. KOSCHADE SE, Stratmann JA, Finkelmeier F, Wagner S, et al
    Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.
    Ann Hematol. 2022 May 20. pii: 10.1007/s00277-022-04862.
    PubMed     Abstract available


  410. ZENG Q, Xiang B, Liu Z
    Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
    Ann Hematol. 2022 May 16. pii: 10.1007/s00277-022-04863.
    PubMed     Abstract available


  411. PODVIN B, Guermouche H, Roynard P, Goursaud L, et al
    Subclonal acquisition of a BCR::ABL1 fusion in a chronic myelomonocytic leukemia.
    Ann Hematol. 2022 May 13. pii: 10.1007/s00277-022-04861.
    PubMed    


  412. SHARMA R, Jani C
    Mapping incidence and mortality of leukemia and its subtypes in 21 world regions in last three decades and projections to 2030.
    Ann Hematol. 2022 May 10. pii: 10.1007/s00277-022-04843.
    PubMed     Abstract available


  413. BOQUOI A, Banahan SM, Mohring A, Savickaite I, et al
    Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.
    Ann Hematol. 2022;101:1031-1038.
    PubMed     Abstract available


  414. HOFER KD, Schanz U, Schwotzer R, Nair G, et al
    Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10 years.
    Ann Hematol. 2022;101:1097-1106.
    PubMed     Abstract available


  415. WANG Y, Hou W, Li H, Tian X, et al
    Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
    Ann Hematol. 2022;101:1039-1047.
    PubMed     Abstract available


  416. SATO M, Yasunaga M, Ohzu M, Toyama K, et al
    Successful diagnosis of veno-occlusive disease caused by inotuzumab ozogamicin through minimal-invasive angiography: a case report.
    Ann Hematol. 2022;101:1153-1155.
    PubMed    


  417. HAZENBERG CLE, Diepstra A, Santing M, Huls GA, et al
    Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment.
    Ann Hematol. 2022;101:1133-1134.
    PubMed    


  418. SHALLIS RM, Pucar D, Perincheri S, Gore SD, et al
    Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy.
    Ann Hematol. 2022;101:1145-1147.
    PubMed    


    April 2022
  419. SEKERES MA, Schuster M, Joris M, Krauter J, et al
    A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
    Ann Hematol. 2022 Apr 30. pii: 10.1007/s00277-022-04853.
    PubMed     Abstract available


  420. LI Y, Tang T, Xiao J, Li B, et al
    Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis.
    Ann Hematol. 2022 Apr 20. pii: 10.1007/s00277-022-04840.
    PubMed     Abstract available


  421. WANG Y, Wang T, Yu Y, Wang Q, et al
    Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
    Ann Hematol. 2022 Apr 18. pii: 10.1007/s00277-022-04795.
    PubMed     Abstract available


  422. LAUW MIS, Hakim N, Arora S, Prakash S, et al
    A case of plasma cell neoplasm-associated chronic neutrophilic leukemia with ASXL1 and JAK2V617F mutations.
    Ann Hematol. 2022 Apr 14. pii: 10.1007/s00277-022-04834.
    PubMed    


  423. GREINER SM, Marklin M, Holzmayer S, Kaban K, et al
    Identification of CD105 (endoglin) as novel risk marker in CLL.
    Ann Hematol. 2022;101:773-780.
    PubMed     Abstract available


    March 2022
  424. MORIMOTO S, Kondo T, Taya T, Matsuo H, et al
    Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA.
    Ann Hematol. 2022 Mar 26. pii: 10.1007/s00277-022-04825.
    PubMed    


  425. LI Y, Dai H, Yao D, Gao X, et al
    Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission.
    Ann Hematol. 2022 Mar 26. pii: 10.1007/s00277-022-04823.
    PubMed    


  426. TSUSHIMA T, Sato N, Guo YM, Uchiyama S, et al
    Combination therapy with low doses of ponatinib and steroids in elderly and frail patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2022 Mar 24. pii: 10.1007/s00277-022-04796.
    PubMed    


  427. CHAUHAN P, Gupta A, Gopinathan M, Sanjeev, et al
    Real-world challenges in the management of acute myeloid leukemia: a single-center experience from North India.
    Ann Hematol. 2022 Mar 24. pii: 10.1007/s00277-022-04814.
    PubMed     Abstract available


  428. UMINSKI K, Khalife R, Kekre N, Tinmouth A, et al
    Acquired hemophilia A following allogeneic stem cell transplantation for acute lymphoblastic leukemia.
    Ann Hematol. 2022 Mar 21. pii: 10.1007/s00277-022-04819.
    PubMed    


  429. CAETANO DOS SANTOS FL, Michalek IM, Wojciechowska U, Didkowska J, et al
    Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999-2020.
    Ann Hematol. 2022 Mar 15. pii: 10.1007/s00277-022-04758.
    PubMed     Abstract available


  430. BI X, French Z, Palmisiano N, Wen KY, et al
    The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions.
    Ann Hematol. 2022 Mar 14. pii: 10.1007/s00277-022-04812.
    PubMed     Abstract available


  431. ROBIN JB, Theron A, Quittet P, Exbrayat C, et al
    Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.
    Ann Hematol. 2022 Mar 12. pii: 10.1007/s00277-022-04779.
    PubMed     Abstract available


  432. ROSETTI M, De la Salle B, Farneti G, Clementoni A, et al
    The added value of digital morphological analysis in the evaluation of peripheral blood films: the report of an UKNEQAS external quality assessment sample.
    Ann Hematol. 2022;101:729-730.
    PubMed    


    February 2022
  433. HERMEL DJ, Cheng B, Bhangoo MS, Burian C, et al
    Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine.
    Ann Hematol. 2022 Feb 26. pii: 10.1007/s00277-022-04800.
    PubMed     Abstract available


  434. BAYSAL M, Gursoy V, Hunutlu FC, Erkan B, et al
    The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study.
    Ann Hematol. 2022 Feb 21. pii: 10.1007/s00277-022-04798.
    PubMed     Abstract available


  435. ROBAK E, Jesionek-Kupnicka D, Stelmach P, Kupnicki P, et al
    Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab.
    Ann Hematol. 2022 Feb 21. pii: 10.1007/s00277-022-04753.
    PubMed    


  436. TANG G, Zou Y, Wang SA, Borthakur G, et al
    3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant.
    Ann Hematol. 2022 Feb 20. pii: 10.1007/s00277-022-04767.
    PubMed     Abstract available


  437. FU W, Huang A, Tang G, Yang J, et al
    A case report of BCR-ABL1 rearrangement in de novo adult T-cell lymphoblastic leukemia/lymphoma with normal karyotype.
    Ann Hematol. 2022 Feb 14. pii: 10.1007/s00277-022-04791.
    PubMed    


  438. MARTELLA F, Cerrano M, Di Cuonzo D, Secreto C, et al
    Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.
    Ann Hematol. 2022 Feb 7. pii: 10.1007/s00277-022-04770.
    PubMed     Abstract available


  439. KEREN-FROIM N, Heering G, Sharvit G, Zlotnik M, et al
    ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.
    Ann Hematol. 2022;101:309-316.
    PubMed     Abstract available


  440. SCHMITZ-FEUERHAKE I, Frentzel-Beyme R, Wolff R
    Non-Hodgkin lymphomas and ionizing radiation: case report and review of the literature.
    Ann Hematol. 2022;101:243-250.
    PubMed     Abstract available


  441. DI GIACOMO D, Quintini M, Pierini V, Pellanera F, et al
    Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement.
    Ann Hematol. 2022;101:297-307.
    PubMed     Abstract available


  442. DUNN WG, Gu MS, Fabre MA, Cooper J, et al
    The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients.
    Ann Hematol. 2022;101:443-445.
    PubMed    


    January 2022
  443. BAEK J, Kim MK, Gu MJ
    Myelolipoma/extramedullary hematopoiesis within adrenal cortical adenoma increased in size during chronic myelogenous leukemia treatment.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-022-04768.
    PubMed    


  444. FREDMAN D, Moshe Y, Wolach O, Heering G, et al
    Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-021-04738.
    PubMed     Abstract available


  445. QIU L, Nunez CA, Tang G, Cuglievan B, et al
    A rare case of acute megakaryoblastic leukemia with t(11;17)(q23;q21) and KMT2A::MLLT6 fusion.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-022-04769.
    PubMed    


  446. MELLADO-GAZQUEZ A, Gomez-Nunez MR, Jurado-Herrera S, Prats-Martin C, et al
    Multiple erythrophagocytosis by erythroid blasts in acute myeloid leukemia with BCR-ABL1.
    Ann Hematol. 2022 Jan 27. pii: 10.1007/s00277-021-04742.
    PubMed    


  447. DUTTA S, Moritz J, Pregartner G, Thallinger GG, et al
    Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
    Ann Hematol. 2022 Jan 26. pii: 10.1007/s00277-022-04766.
    PubMed     Abstract available


  448. MAO YY, Cai HC, Shen KN, Chang L, et al
    Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study.
    Ann Hematol. 2022 Jan 17. pii: 10.1007/s00277-022-04764.
    PubMed     Abstract available


  449. ONISHI A, Fuji S, Kitano S, Maeshima AM, et al
    Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.
    Ann Hematol. 2022 Jan 15. pii: 10.1007/s00277-022-04760.
    PubMed     Abstract available


  450. TISO F, Koorenhof-Scheele TN, Huys E, Martens JHA, et al
    Genetic diversity within leukemia-associated immunophenotype-defined subclones in AML.
    Ann Hematol. 2022 Jan 13. pii: 10.1007/s00277-021-04747.
    PubMed     Abstract available


  451. HARADA K, Mizuno S, Yano S, Takami A, et al
    Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia.
    Ann Hematol. 2022 Jan 6. pii: 10.1007/s00277-021-04731.
    PubMed     Abstract available


  452. ZEIDAN AM, DeAngelo DJ, Palmer J, Seet CS, et al
    Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
    Ann Hematol. 2022 Jan 4. pii: 10.1007/s00277-021-04734.
    PubMed     Abstract available


  453. KONUMA T, Ooi J, Nagayama H, Tomonari A, et al
    Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.
    Ann Hematol. 2022;101:177-189.
    PubMed     Abstract available


  454. GUPTA A, Desai N, Sanjeev, Chauhan P, et al
    Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India.
    Ann Hematol. 2022;101:69-79.
    PubMed     Abstract available


  455. SAKURAI M, Nannya Y, Yamazaki R, Yamaguchi K, et al
    Germline RUNX1 translocation in familial platelet disorder with propensity to myeloid malignancies.
    Ann Hematol. 2022;101:237-239.
    PubMed    


    December 2021
  456. DALELA D, Bledsoe JR, Patel SA
    Clonal IgH gene rearrangements identify Richter's transformation to diffuse large B cell lymphoma.
    Ann Hematol. 2021;100:3075-3077.
    PubMed    


  457. PULIDO-PEREZ A, Bergon-Sendin M, Mateos-Mayo A, Parra-Blanco V, et al
    Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib.
    Ann Hematol. 2021;100:3065-3066.
    PubMed    


    November 2021
  458. ARCANI R, Colle J, Cauchois R, Koubi M, et al
    Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.
    Ann Hematol. 2021;100:2799-2803.
    PubMed     Abstract available


  459. REINERT J, Beitzen-Heineke A, Wethmar K, Stelljes M, et al
    Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin.
    Ann Hematol. 2021;100:2727-2732.
    PubMed     Abstract available


  460. MAYER MC, Berg JL, Perfler B, Hatzl S, et al
    miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.
    Ann Hematol. 2021;100:2845-2847.
    PubMed    


    October 2021
  461. STANGANELLI C, Torres DC, Ortega C, Marquez ME, et al
    Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients.
    Ann Hematol. 2021 Oct 28. pii: 10.1007/s00277-021-04703.
    PubMed     Abstract available


  462. MENDES FR, da Silva WF, da Costa Bandeira de Melo R, Silveira DRA, et al
    Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting.
    Ann Hematol. 2021 Oct 21. pii: 10.1007/s00277-021-04687.
    PubMed     Abstract available


  463. ZHANG Y, Qian JJ, Shen YJ, Hang SJ, et al
    The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 18. pii: 10.1007/s00277-021-04699.
    PubMed    


  464. HOU HA, Tzeng HE, Liu HY, Chou WC, et al
    Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015.
    Ann Hematol. 2021 Oct 13. pii: 10.1007/s00277-021-04670.
    PubMed     Abstract available


  465. PASVOLSKY O, Shimony S, Ram R, Shimoni A, et al
    Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Ann Hematol. 2021 Oct 9. pii: 10.1007/s00277-021-04693.
    PubMed     Abstract available


  466. UMINSKI K, Khalife R, Fulcher J, Duffett L, et al
    Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 6. pii: 10.1007/s00277-021-04688.
    PubMed    


  467. CHOI HS, Hong J, Hwang SM, Lee JH, et al
    Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Ann Hematol. 2021;100:2567-2574.
    PubMed     Abstract available


  468. SHAH N, Rakszawski K, Nickolich M, Ehmann C, et al
    Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion.
    Ann Hematol. 2021;100:2585-2592.
    PubMed     Abstract available


  469. BALLO O, Eladly F, Koschade S, Buttner S, et al
    Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy.
    Ann Hematol. 2021;100:2603-2611.
    PubMed     Abstract available


  470. DAS N, Gupta R, Gupta SK, Bakhshi S, et al
    Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.
    Ann Hematol. 2021;100:2487-2500.
    PubMed     Abstract available


  471. SAVASAN S, Buck S, Gadgeel M, Poulik J, et al
    Persistent pseudo-Pelger-Huet anomaly.
    Ann Hematol. 2021;100:2661-2663.
    PubMed    


  472. MARRA A, Martino G, Scarpelli N, Perriello V, et al
    Collision diffuse large B cell lymphoma and myeloid sarcoma in the liver.
    Ann Hematol. 2021;100:2649-2651.
    PubMed    


    September 2021
  473. KIM TH, Choi YW, Ahn MS, Choi YS, et al
    Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia.
    Ann Hematol. 2021 Sep 30. pii: 10.1007/s00277-021-04673.
    PubMed     Abstract available


  474. ZHAO P, Ni M, Ma D, Fang Q, et al
    Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Sep 27. pii: 10.1007/s00277-021-04674.
    PubMed     Abstract available


  475. FAGUNDES EM, Neto NN, Caldas LM, Aragao JR, et al
    Mortality by COVID-19 in adults with acute myeloid leukemia: a survey with hematologists in Brazil.
    Ann Hematol. 2021 Sep 17. pii: 10.1007/s00277-021-04659.
    PubMed    


  476. XU RZ, Karsan A, Xu Z, Berry BR, et al
    A rare de novo pure erythroid leukemia with JAK2 R683S mutation.
    Ann Hematol. 2021 Sep 4. pii: 10.1007/s00277-021-04657.
    PubMed    


  477. YANADA M, Konuma T, Yamasaki S, Mizuno S, et al
    The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia.
    Ann Hematol. 2021 Sep 3. pii: 10.1007/s00277-021-04661.
    PubMed     Abstract available


  478. FUJI S, Kida S, Nakata K, Morishima T, et al
    Long-term trends in the clinical outcomes of patients with acute myeloid leukemia: a population-based real-world data analysis using the Osaka Cancer Registry.
    Ann Hematol. 2021 Sep 3. pii: 10.1007/s00277-021-04631.
    PubMed     Abstract available


  479. HEINICKE T, Krahl R, Kahl C, Cross M, et al
    Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
    Ann Hematol. 2021;100:2387-2398.
    PubMed     Abstract available


  480. QI J, Zhang R, Cai C, Wang H, et al
    HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant.
    Ann Hematol. 2021;100:2351-2361.
    PubMed     Abstract available


  481. CHEN X, Liu C, Zhang A, Wu W, et al
    Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
    Ann Hematol. 2021;100:2269-2277.
    PubMed     Abstract available


  482. SIM JPY, Lie AKW, Ng MY, Kwong YL, et al
    Durable remission of T cell lymphoblastic lymphoma relapsing after allogeneic haematopoietic stem cell transplantation with a single low dose of nivolumab.
    Ann Hematol. 2021;100:2399-2402.
    PubMed    


    August 2021
  483. GUERY R, Suarez F, Lanternier F, Bougnoux ME, et al
    Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa.
    Ann Hematol. 2021 Aug 13. pii: 10.1007/s00277-021-04622.
    PubMed     Abstract available


  484. TACHIBANA T, Kanda J, Ishizaki T, Najima Y, et al
    Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.
    Ann Hematol. 2021 Aug 6. pii: 10.1007/s00277-021-04607.
    PubMed     Abstract available


  485. MIAN AA, Haberbosch I, Khamaisie H, Agbarya A, et al
    Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K).
    Ann Hematol. 2021;100:2023-2029.
    PubMed     Abstract available


  486. WELLBROCK J, Behrmann L, Muschhammer J, Modemann F, et al
    The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia.
    Ann Hematol. 2021 Aug 1. pii: 10.1007/s00277-021-04602.
    PubMed     Abstract available


    July 2021
  487. MI R, Chen L, Yang H, Zhang Y, et al
    Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia.
    Ann Hematol. 2021 Jul 27. pii: 10.1007/s00277-021-04621.
    PubMed     Abstract available


  488. MATSUDA K, Jo T, Toyama K, Nakazaki K, et al
    Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan.
    Ann Hematol. 2021 Jul 26. pii: 10.1007/s00277-021-04620.
    PubMed     Abstract available


  489. ALRAWASHDH N, Sweasy J, Erstad B, McBride A, et al
    Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04600.
    PubMed     Abstract available


  490. ELNAIR R, Ellithi M, Kallam A, Shostrom V, et al
    Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04603.
    PubMed     Abstract available


  491. KONG J, Qin YZ, Zhao XS, Hou Y, et al
    Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04606.
    PubMed     Abstract available


  492. MICHAELIS S, Pichler A, Stelzer I, Schoffmann L, et al
    Aggressive NK-cell leukemia with hemophagocytosis in a Caucasian patient.
    Ann Hematol. 2021 Jul 16. pii: 10.1007/s00277-021-04585.
    PubMed    


  493. HARA R, Onizuka M, Kikkawa E, Shiraiwa S, et al
    Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2021 Jul 11. pii: 10.1007/s00277-021-04587.
    PubMed     Abstract available


  494. BARZEGAR M, Farsani MA, Rafiee M, Amiri V, et al
    Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARalpha transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04579.
    PubMed     Abstract available


  495. TANIGAWA T, Sakurai M, Kato J, Mizuno K, et al
    Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04586.
    PubMed    


  496. GREIL R, Tedeschi A, Moreno C, Anz B, et al
    Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
    Ann Hematol. 2021;100:1733-1742.
    PubMed     Abstract available


  497. GADGEEL M, AlQanber B, Buck S, Taub JW, et al
    Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis.
    Ann Hematol. 2021;100:1695-1700.
    PubMed     Abstract available


    June 2021
  498. VIRK H, Rana S, Sharma P, Bose PL, et al
    Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
    Ann Hematol. 2021 Jun 22. pii: 10.1007/s00277-021-04574.
    PubMed     Abstract available


  499. WYSOCKA-SLOWIK A, Gil L, Slebioda Z, Kregielczak A, et al
    Oral mucositis in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation in relation to the conditioning used prior to transplantation.
    Ann Hematol. 2021 Jun 12. pii: 10.1007/s00277-021-04568.
    PubMed     Abstract available


  500. KRECAK I, Cengic M, Skoric I, Nakic M, et al
    Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Ann Hematol. 2021 Jun 10. pii: 10.1007/s00277-021-04570.
    PubMed    


  501. DOU X, Zheng F, Zhang L, Jin J, et al
    Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study.
    Ann Hematol. 2021 Jun 5. pii: 10.1007/s00277-021-04544.
    PubMed     Abstract available


  502. AL-SARAYFI D, Meeuwes FO, Munnink TO, Plattel W, et al
    Successful treatment of hairy cell leukemia variant with obinutuzumab.
    Ann Hematol. 2021 Jun 4. pii: 10.1007/s00277-021-04559.
    PubMed    


  503. LARIBI K, Sobh M, Ghez D, Baugier de Materre A, et al
    Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review.
    Ann Hematol. 2021;100:1359-1376.
    PubMed     Abstract available


  504. ZENG Z, Ly C, Daver N, Cortes J, et al
    High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
    Ann Hematol. 2021;100:1485-1496.
    PubMed     Abstract available


    May 2021
  505. HEUSER M, Smith BD, Fiedler W, Sekeres MA, et al
    Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Ann Hematol. 2021 May 12. pii: 10.1007/s00277-021-04545.
    PubMed    


  506. KONG J, Chen N, Li M, Zhang J, et al
    Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2021 May 6. pii: 10.1007/s00277-021-04530.
    PubMed    


  507. DEVOS T, Havelange V, Theunissen K, Meers S, et al
    Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Ann Hematol. 2021 May 4. pii: 10.1007/s00277-021-04507.
    PubMed     Abstract available


  508. GONZALEZ JS, Perusini MA, Basquiera AL, Alfonso G, et al
    Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients.
    Ann Hematol. 2021 May 1. pii: 10.1007/s00277-021-04539.
    PubMed     Abstract available


  509. SALAMONOWICZ-BODZIOCH M, Fraczkiewicz J, Czyzewski K, Zajac-Spychala O, et al
    Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation.
    Ann Hematol. 2021;100:1283-1293.
    PubMed     Abstract available


  510. TANG KHK, Ip AHW, Kwong YL
    Clonal derivation of sequential seminoma and acute megakaryoblastic leukaemia.
    Ann Hematol. 2021;100:1337-1339.
    PubMed    


  511. HORIUCHI M, Yoshida M, Yamasaki K, Sakagami R, et al
    Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
    Ann Hematol. 2021;100:1329-1331.
    PubMed    


  512. BERNARDI S, Zanaglio C, Farina M, Polverelli N, et al
    dsDNA from extracellular vesicles (EVs) in adult AML.
    Ann Hematol. 2021;100:1355-1356.
    PubMed    


    April 2021
  513. MARTINEZ SANCHEZ MP, Megias-Vericat JE, Rodriguez-Veiga R, Vives S, et al
    A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Ann Hematol. 2021 Apr 29. pii: 10.1007/s00277-021-04542.
    PubMed     Abstract available


  514. ZHAO H, Sun J, Yan L, Jin B, et al
    Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study.
    Ann Hematol. 2021 Apr 24. pii: 10.1007/s00277-021-04533.
    PubMed     Abstract available


  515. KE P, Zhang X, Liu S, Zhu Q, et al
    The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
    Ann Hematol. 2021 Apr 22. pii: 10.1007/s00277-021-04528.
    PubMed     Abstract available


  516. ONAKA T, Kato-Ogura A, Otsuka Y, Iwai F, et al
    A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.
    Ann Hematol. 2021 Apr 12. pii: 10.1007/s00277-021-04516.
    PubMed    


  517. OWATTANAPANICH W, Herzig J, Jahn N, Panina E, et al
    Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Ann Hematol. 2021 Apr 10. pii: 10.1007/s00277-021-04513.
    PubMed     Abstract available


  518. QIAN Y, Chen Y, Li X
    CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
    Ann Hematol. 2021 Apr 6. pii: 10.1007/s00277-021-04491.
    PubMed     Abstract available


  519. RETTIG AR, Ihorst G, Bertz H, Lubbert M, et al
    Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis.
    Ann Hematol. 2021 Apr 1. pii: 10.1007/s00277-021-04494.
    PubMed     Abstract available


    January 2021
  520. LIU J, Shen L, Huang H, Gao X, et al
    A rare case of donor-derived promyelocytic sarcoma in a kidney transplant recipient.
    Ann Hematol. 2021;100:295-296.
    PubMed    


    June 2020
  521. HOCHMAN MJ, Martin DB
    Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.
    Ann Hematol. 2020 Jun 16. pii: 10.1007/s00277-020-04091.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.